

## CLINICAL/NARRATIVE REVIEW

# *Helicobacter Pylori* “Test-and-Treat” Strategy for Management of Dyspepsia: A Comprehensive Review

Javier P. Gisbert, MD, PhD<sup>1</sup> and Xavier Calvet, MD, PhD<sup>2</sup>

**OBJECTIVES:** Deciding on whether the *Helicobacter pylori* test-and-treat strategy is an appropriate diagnostic–therapeutic approach for patients with dyspepsia invites a series of questions. The aim present article addresses the test-and-treat strategy and attempts to provide practical conclusions for the clinician who diagnoses and treats patients with dyspepsia.

**METHODS:** Bibliographical searches were performed in MEDLINE using the keywords *Helicobacter pylori*, test-and-treat, and dyspepsia. We focused mainly on data from randomized controlled trials (RCTs), systematic reviews, meta-analyses, cost-effectiveness analyses, and decision analyses.

**RESULTS:** Several prospective studies and decision analyses support the use of the test-and-treat strategy, although we must be cautious when extrapolating the results from one geographical area to another. Many factors determine whether this strategy is appropriate in each particular area. The test-and-treat strategy will cure most cases of underlying peptic ulcer disease, prevent most potential cases of gastroduodenal disease, and yield symptomatic benefit in a minority of patients with functional dyspepsia. Future studies should be able to stratify dyspeptic patients according to their likelihood of improving after treatment of infection by *H. pylori*.

**CONCLUSIONS:** The test-and-treat strategy will cure most cases of underlying peptic ulcer disease and prevent most potential cases of gastroduodenal disease. In addition, a minority of infected patients with functional dyspepsia will gain symptomatic benefit. Several prospective studies and decision analyses support the use of the test-and-treat strategy. The test-and-treat strategy is being reinforced by the accumulating data that support the increasingly accepted idea that “the only good *H. pylori* is a dead *H. pylori*”.

*Clinical and Translational Gastroenterology* (2013) 4, e32; doi:10.1038/ctg.2013.3; published online 28 March 2013

**Subject Category:** Stomach

## INTRODUCTION

Although many definitions of dyspepsia have been proposed, perhaps the most widely accepted is that of “persistent or recurrent abdominal pain or discomfort in the upper abdomen”. Dyspepsia is a major health problem, whose prevalence reaches > 10% among adult populations.<sup>1–3</sup> Approximately 20 to 30% of people in the community each year report chronic or recurrent dyspeptic symptoms,<sup>4,5</sup> and consultations for dyspepsia account for up to 40% of referrals among gastroenterology outpatients.<sup>6</sup> Furthermore, the already high costs of diagnosis and treatment of dyspepsia have been increasing.<sup>7</sup>

Based on prospective studies of subjects who report dyspeptic symptoms for the first time, incidence is approximately 1% per year.<sup>5,8</sup> Most patients with unexplained dyspeptic symptoms continue to be symptomatic in the long term despite periods of remission.<sup>9</sup> Approximately one in two subjects seeks health care for dyspeptic symptoms at some time in their life.<sup>10</sup>

The initial approach to diagnosis of dyspepsia has traditionally been oral endoscopy; however, generalized use of this approach does not seem to be a realistic option. Consequently, other diagnostic strategies based on the

response to empirical treatment have been used, although none has proved to be definitively useful. In empirical therapy-based strategies, endoscopy is used only in cases of lack of response to antisecretory or promotility agents. However, this policy has been reported to achieve only modest savings and has been considered to be inappropriate: the initial saving achieved by avoiding endoscopy is lost, as the likelihood of eventual endoscopy increases during follow-up.<sup>11</sup>

Recently proposed strategies are based on the non-invasive diagnosis of *Helicobacter pylori* infection. The most outstanding is the so-called “test-and-treat” strategy.<sup>12</sup> As its name indicates, this strategy is based on the investigation of the presence of *H. pylori* and its subsequent eradication when detected. Symptomatic treatment, on the other hand, could be given to non-infected patients. The test-and-scope strategy<sup>13,14</sup>—performing a test to detect *H. pylori* in all patients and endoscopy only in those who are shown to be infected—has been considered less useful and is therefore not applied in clinical practice.<sup>13,14</sup>

Deciding on whether the test-and-treat strategy is an appropriate diagnostic–therapeutic approach invites a series

<sup>1</sup>Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain and <sup>2</sup>Department of Gastroenterology, Hospital de Sabadell, Departament de Medicina, Universitat Autònoma de Barcelona and CIBEREHD, Barcelona, Spain

Correspondence: Javier P. Gisbert, MD, PhD, Playa de Mojácar 29. Urb. Bonanza, 28669 Boadilla del Monte, Madrid, Spain. E-mail: gisbert@meditex.es

Received 1 December 2012; accepted 31 January 2013

of questions: is there enough scientific evidence to recommend its use? Is this approach universally valid, or does its efficiency depend on factors that change from one geographic area to another? Is this strategy affected by non-financial considerations? The present article addresses the test-and-treat strategy and attempts to provide practical conclusions for the clinician who diagnoses and treats patients with dyspepsia. Thus, the aspects of the test-and-treat strategy to be reviewed are as follows: (i) age threshold at which test-and-treat could be applied; (ii) cost and availability of endoscopy; (iii) prevalence of *H. pylori* infection in the study population; (iv) type of diagnostic methods used to detect *H. pylori* infection; (v) proportion of *H. pylori*-positive patients who have or who are going to develop peptic ulcer and the proportion of ulcers attributable to *H. pylori*; (vi) role of *H. pylori* in the development of gastric cancer; (vii) role of *H. pylori* in functional dyspepsia; (viii) efficacy, cost, and adverse effects of *H. pylori* eradication therapy; (ix) risk of missing serious diseases; (x) use of endoscopy or an empirical proton pump inhibitor (PPI) after failure of the test-and-treat strategy; (xi) patient satisfaction; (xii) follow-up time; and (xiii) setting of testing (primary care vs. secondary care).

## SEARCH STRATEGY

Bibliographical searches were performed in MEDLINE up to July 2012 using the following keywords (all fields): (“*Helicobacter pylori*” OR “*H. pylori*”) AND (“test-and-treat” OR “test and treat” OR dyspepsia). Articles published in any language were included. Reference lists from the trials selected in the electronic search were hand-searched to identify further relevant trials. Abstracts of the articles selected in each of the multiple searches were reviewed, and those meeting the inclusion criteria (i.e., addressing the *H. pylori* test-and-treat strategy in dyspeptic patients) were selected. References from reviews on management of dyspepsia were also examined to identify articles meeting the inclusion criteria. In the case of duplicate reports or studies reporting results from the same study population, only the most recent published results were used. We focused mainly on data from randomized controlled trials (RCTs), systematic reviews, meta-analyses, cost-effectiveness analyses, and decision analyses published in the literature.

## RATIONALE OF THE TEST-AND-TREAT STRATEGY

Even after performing several diagnostic tests, biochemical or organic disturbances explaining dyspeptic symptoms cannot be found in most cases. Such patients can be classified as having functional or non-ulcer dyspepsia.<sup>15</sup> However, because patients with dyspepsia may have serious underlying diseases, the initial evaluation has traditionally included endoscopic examination of the upper gastrointestinal tract. The main advantage of endoscopy is its high diagnostic accuracy. A normal endoscopy result reassures both the patient who consults owing to fear of having a serious disease and the physician.

However, endoscopy has several disadvantages: it is uncomfortable, expensive, and not free of risk. In addition, as endoscopy centers have been meeting increasing

demands,<sup>16</sup> the technique frequently involves prolonged waiting times. Furthermore, a large proportion of endoscopy findings are normal and thus do not contribute to management. In summary, although a strategy including endoscopic evaluation of the upper gastrointestinal tract in all patients with dyspepsia is obviously a theoretical option, it is not realistic in clinical practice.

As a consequence of the aforementioned problems, particularly limited resources and the large number of normal findings, several diagnostic policies have been proposed for selecting patients with symptoms of dyspepsia who are expected to benefit most from the procedure, thus reducing the number of endoscopies. To avoid the theoretical risk of delaying the diagnosis of a malignant neoplasm, these strategies have been recommended only in “young” patients (see later for the definition of this variable), with no “alarm” symptoms (such as unexplained weight loss, progressive dysphagia, recurrent vomiting, anemia, bleeding, or an abdominal mass); otherwise, endoscopy should be performed.

## RANDOMIZED CLINICAL TRIALS

The test-and-treat strategy has been compared with prompt endoscopy and with empirical therapy. In this section, these two relevant comparisons will be evaluated individually.

**(1) Test-and-treat vs. prompt endoscopy.** The test-and-treat strategy has been compared with prompt endoscopy in eight RCTs (Table 1),<sup>17–24</sup> which differ in important ways: in three trials<sup>17,19,20</sup> patients were recruited and randomized at the endoscopy unit after their general practitioner had referred them for investigation; in five trials<sup>18,21–24</sup> patients were randomized in primary care. It is noteworthy that the studies by Jones *et al.*<sup>18</sup> and Duggan *et al.*<sup>24</sup> used near-patient serology, which has very poor accuracy for the diagnosis of *H. pylori* infection; this important drawback markedly reduces the reliability of results.<sup>25</sup> Furthermore, Arents *et al.*<sup>21</sup> used the serology result from a venous blood sample to diagnose *H. pylori* infection; although more reliable than office serology, this test is far less accurate than the <sup>13</sup>C-urea breath test, which was the diagnostic test in the remaining studies. Three studies recruited only individuals <45 years of age,<sup>17,18,23</sup> two studies set the age cutoff at 55 years,<sup>20,21</sup> and no age limit was applied in the remaining three studies.<sup>19,22,24</sup> Most studies randomized participants to *H. pylori* testing or endoscopy, but Heaney *et al.*<sup>17</sup> randomized only *H. pylori*-positive patients to either treatment or prompt endoscopy.

None of the studies demonstrated that prompt endoscopy enabled symptoms to be cured. One small study reported significantly lower symptom scores in subjects randomized to test-and-treat at 12 months.<sup>17</sup> Seven of the above-mentioned trials reported cost data and all demonstrated a significant reduction in the total number of endoscopies with a test-and-treat strategy,<sup>18–24</sup> with two studies reporting that test-and-treat was the most cost-effective management strategy.<sup>22,24</sup> Follow-up in all these studies was limited to 12 months, so it is uncertain whether the observed cost reductions generated using the test-and-treat strategy instead of prompt endoscopy is sustained in the long term. Interestingly, Lassen *et al.*<sup>26</sup>

**Table 1** Randomized controlled trials comparing test-and-treat strategy vs. prompt endoscopy

Author	Year of publication	Country	Number of patients <sup>a</sup>	Age limit (years)	Setting	H. pylori diagnostic methods	H. pylori infection prevalence <sup>a</sup>	H. pylori eradication treatment <sup>a</sup>	H. pylori eradication rate <sup>a</sup>	Follow-up time (months)	Outcome measures
Heaney <i>et al.</i> <sup>17</sup>	1999	UK	52	<45	Secondary care	UBT	100%	PPI + C + N	78%	12	Dyspeptic symptoms Quality of life
Jones <i>et al.</i> <sup>18</sup>	1999	UK	141	<45	Primary care	Office-based serology	41%	Unknown <sup>b</sup>	Unknown	12	Dyspeptic symptoms Costs/use of medical resources
Lassen <i>et al.</i> <sup>19c</sup>	2000	Denmark	250	No age limit <sup>d</sup>	Primary and secondary care	UBT	26%	PPI + A + N	87%	12	Dyspeptic symptoms Quality of life Patient satisfaction Costs/use of medical resources
McColl <i>et al.</i> <sup>20</sup>	2002	UK	356	<55	Secondary care	UBT	48%	PPI + C + A	84%	12	Dyspeptic symptoms Quality of life Patient satisfaction Costs/use of medical resources
Arents <i>et al.</i> <sup>21</sup>	2003	The Netherlands	141	<55	Primary care	Serology	38%	PPI + A + C/N	87	12	Dyspeptic symptoms Quality of life Patient satisfaction Costs/use of medical resources
Hu <i>et al.</i> <sup>22</sup>	2006	China	78	No age limit <sup>d</sup>	Primary care	UBT	53%	PPI + C + A	Unknown <sup>e</sup>	12	Dyspeptic symptoms Patient satisfaction Medication consumption Costs/use of medical resources
Mahadeva <i>et al.</i> <sup>23</sup>	2008	Malaysia	222	<45	Primary care	UBT	35%	PPI + C + A	Unknown <sup>f</sup>	12	Dyspeptic symptoms Quality of life Patient satisfaction Costs/use of medical resources
Duggan <i>et al.</i> <sup>24</sup>	2009	UK	198	No age limit <sup>d</sup>	Primary care	Near-patient serology	23%	PPI + C + N	Unknown	12	Dyspeptic symptoms Quality of life Patient satisfaction Costs/use of medical resources

Abbreviation: UBT, <sup>13</sup>C-urea breath test.

H. pylori eradication treatment: A, amoxicillin; C, clarithromycin; N, nitroimidazole; PPI, proton pump inhibitor.

<sup>a</sup>In the test-and-treat group.

<sup>b</sup>No specific regimen was determined, but PPI-based triple therapy was recommended.

<sup>c</sup>The long-term results of this study have been published.<sup>26</sup>

<sup>d</sup>Age threshold at 70 years.

<sup>e</sup>Eradication rate was found to be 88% locally.

<sup>f</sup>Eradication rate was found to be 91% locally.

evaluated subjects 6 years after enrollment. The rates of endoscopy and the need for acid suppression therapy in those managed with a test-and-treat strategy remained as low as that observed at 12 months. The prevalence of dyspeptic symptoms was similar in both arms (test-and-treat and endoscopy). See “Follow-up time” section (below) for more detailed information of this long-term follow-up study.

**(2) Test-and-treat vs. empirical antisecretory therapy.**

Four RCTs have compared the test-and-treat strategy with empirical acid suppression therapy in primary care (Table 2).<sup>24,27–29</sup> One of these studies<sup>27</sup> was performed entirely in secondary care. The patients were followed-up intensively every 2 months, and all those who were still symptomatic at 4 weeks or who experienced recurrence of symptoms at any point during follow-up were offered endoscopy. Around 90% of the PPI-treated group and 60% of the test-and-treat group underwent endoscopy owing to recurrence of symptoms: this difference was very statistically significant in favor of the test-and-treat strategy. As mentioned above, the study by Duggan *et al.*<sup>24</sup> used near-patient serology, which has poor accuracy for the diagnosis of H. pylori infection.<sup>25</sup> This may have led to a considerable underestimation of the efficacy of test-and-treat for dyspepsia, as infected individuals could have been incorrectly labeled as being H. pylori-negative and treated with 4 weeks of PPI (rather than eradication therapy), and uninfected patients might have received eradication therapy.<sup>30</sup>

Only Manes *et al.*<sup>27</sup> demonstrated a clear benefit of either test-and-treat or empirical PPI strategies, possibly because theirs was the only study performed in an area of high prevalence of H. pylori. Costs were very similar in both arms in one of these studies.<sup>29</sup> Of the remaining trials, one did not perform a cost analysis, one concluded that empirical acid suppression therapy was probably not cost-effective,<sup>31</sup> and one showed that empirical PPI therapy only became cost-effective when willingness to pay per patient cured was very low (<€215).<sup>24</sup>

Although RCTs generally have the highest quality design, they may have limitations. Thus, wide variability in trial design and outcomes has been reported. The shortcomings of the aforementioned RCTs include lack of agreement on the definition of dyspepsia, use of ineffective H. pylori diagnostic tests or eradication regimens, inadequate sample size, differences in setting (primary vs. secondary care), differences in the upper age limit for inclusion (from <45 to <55 years, or even without age limit), or insufficient length of follow-up. With respect to this last variable, for example, a test-and-treat strategy may not be expected to be superior to the empirical antisecretory therapy in the short term. However, it is conceivable that an H. pylori eradication strategy provides a sustained benefit for many patients, whereas the benefit of antisecretory treatment is expected to fade after the end of the treatment. This sustained benefit could be demonstrated only after long-term follow-up.

**META-ANALYSES**

To evaluate the effectiveness of the test-and-treat strategy, a formal meta-analysis would not be appropriate given the variation in trial design and outcome measures.<sup>32</sup> A qualitative

**Table 2** Randomized controlled trials comparing test-and-treat strategy with empirical antisecretory therapy

Author	Year of publication	Country	Number of patients <sup>a</sup>	Age limit (years)	Setting	<i>H. pylori</i> diagnostic methods	<i>H. pylori</i> infection prevalence <sup>a</sup>	<i>H. pylori</i> eradication treatment <sup>a</sup>	<i>H. pylori</i> eradication rate <sup>a</sup>	Follow-up time (months)	Outcome measures
Manes <i>et al.</i> <sup>27</sup>	2003	Italy	110	< 45	Secondary care	UBT	61%	PPI + C + N	94%	12	Dyspeptic symptoms Costs/use of medical resources
Jarbol <i>et al.</i> <sup>28</sup>	2006	Denmark	250	No age limit	Primary care	UBT	24%	PPI + C + A	Unknown	12	Dyspeptic symptoms Quality of life Patient satisfaction Costs/use of medical resources
Delaney <i>et al.</i> <sup>29</sup>	2008	UK	343	No age limit <sup>b</sup>	Primary care	UBT	29%	PPI + C + N	78%	12	Dyspeptic symptoms Quality of life Patient satisfaction Costs/use of medical resources
Duggan <i>et al.</i> <sup>24</sup>	2009	UK	198	No age limit	Primary care	Near-patient serology test	23%	PPI + C + N	Unknown	12	Dyspeptic symptoms Quality of life Patient satisfaction Costs/use of medical resources

Abbreviation: UBT, <sup>13</sup>C-urea breath test.

*H. pylori* eradication treatment: A, amoxicillin; C, clarithromycin; N, nitroimidazole; PPI, proton pump inhibitor.

<sup>a</sup>In the test-and-treat group.

<sup>b</sup>Age threshold at 65 years.

and semiquantitative review seems to be more appropriate and can still provide useful information to guide the management of dyspepsia.<sup>32</sup>

Conflicting results and incomplete reporting in the aforementioned RCTs means that uncertainty remains over which of these management strategies is the most effective for curing symptoms, and which is the most cost-effective.<sup>33</sup> This issue has been addressed by two individual patient data meta-analyses that have compared test-and-treat with prompt endoscopy,<sup>34</sup> as well as test-and-treat with empirical antisecretory therapy.<sup>30</sup> Access to full data sets enables the meta-analyses to be performed with the individual data of each patient rather than with pooled data, thus increasing the reliability of the results.

**(1) Test-and-treat vs. prompt endoscopy.** The individual patient data meta-analysis performed by Ford *et al.*<sup>34</sup> (including almost 2,000 patients) identified five RCTs comparing prompt endoscopy with test-and-treat. Prompt endoscopy conferred a small but statistically significant benefit on symptoms: the relative risk of symptoms persisting at 12 months was 0.95 (95% confidence interval (CI), 0.92–0.99). In terms of cost-effectiveness, test-and-treat cost \$389 less per patient. Using the net benefit approach, prompt endoscopy did not become cost effective at any realistic level of willingness to pay per patient free of symptoms at the end of follow-up.

This individual patient data meta-analysis clarified the issues left unresolved by the original Cochrane review.<sup>35</sup> The principal difference between the trial-based meta-analysis and that based on individual patient data are that the former found no significant differences in symptom outcome between the two strategies, although significant heterogeneity was observed and the confidence intervals were wide. The individual data-based meta-analysis included cost data, and heterogeneity between trials was reduced, thus allowing the emergence of a small but significant difference in the effect.<sup>34</sup>

The first conclusion of this individual patient data meta-analysis was that prompt endoscopy confers a small benefit in

terms of cure of dyspepsia. One explanation for this benefit may be the reassurance effect of normal endoscopy, an effect that has often been claimed but never proved and that—if it truly exists—seems to be quite short lived.<sup>34</sup> In addition, the trials were unblinded, and the possibility that this might have led to a bias in favor of endoscopy cannot be excluded.<sup>34</sup> Furthermore, prompt endoscopy was generally associated with testing for *H. pylori* and treatment if positive; therefore, some of the benefits of this strategy may in fact be due to eradication of the infection. Finally, it should be noted that large meta-analyses have the power to detect small differences in effect that, although statistically significant, may have little clinical relevance.<sup>34</sup> Thus, the difference in effect was small (relative risk of 0.95), and the statistical significance was borderline (95% CI from 0.92 to 0.99).

The second conclusion of the meta-analysis was that the cost of prompt endoscopy as a first-line approach for the management of dyspepsia in patients without alarm symptoms is prohibitive in everyday clinical practice, with the result that a test-and-treat strategy should be preferred.<sup>34</sup>

**(2) Test-and-treat vs. empirical antisecretory therapy.** The second individual patient data meta-analysis performed by Ford *et al.*<sup>30</sup> pooled data from three RCTs comparing test-and-treat with empirical acid suppression in > 1,500 patients. No significant differences were found in symptoms at 12 months of follow-up. This meta-analysis, however, might be biased both by including the unreliable study by Duggan *et al.*<sup>24</sup> and by excluding a well-performed RCT from Manes *et al.*<sup>27</sup> because it was performed in secondary care. In addition, a detailed analysis raises additional concerns over the validity of the conclusions of the meta-analysis: the study by Delaney *et al.* was performed in an area of very low prevalence of *H. pylori* infection: only 100/265 patients were positive for *H. pylori* and the infection was finally cured in only 57/265. Finally, although the primary end point analysis in the study by Jarbol *et al.*<sup>28</sup> was negative, the secondary end point analysis showed that patients who received eradication therapy had significantly fewer days with dyspeptic

symptoms at 12 months, used less antisecretory therapy, and were more satisfied with their management. Therefore, although this particular meta-analysis concludes that for the initial management of dyspepsia, test-and-treat and empirical PPI therapy perform equally well in terms of symptom resolution, this conclusion may not be applicable everywhere. A more detailed analysis of data strongly suggests that the test-and-treat strategy overcomes empirical PPI therapy for control of symptoms and that the benefit increases as the prevalence of *H. pylori* increases in the dyspeptic population. Finally, the strategy assigned reduced subsequent dyspepsia-related costs among those randomized to test-and-treat compared with those allocated to empirical PPI therapy, although the difference was relatively small and did not achieve statistical significance. As commented on above, this saving could increase further with a longer duration of follow-up.<sup>30</sup>

### PROSPECTIVE STUDIES (NOT RCTS)

Prospective studies, with different designs from those of RCTs, have also evaluated the test-and-treat strategy. Of note, very few studies have prospectively evaluated the test-and-treat strategy, and those that did generally included a limited number of patients. Thus, only a few large-scale studies in a real-life setting are available.

Moayyedi *et al.*<sup>36</sup> compared the proportion of endoscopies carried out in patients aged <40 years during the 5 years before and 2 years after the introduction of a screening and treatment strategy at population level. The authors recorded a 37% reduction in open-access endoscopy performed following the introduction of the <sup>13</sup>C-urea breath test service. Six months after attending the <sup>13</sup>C-urea breath test service, a significant fall in dyspepsia score, general practice dyspepsia consultations, and H<sub>2</sub> receptor antagonist prescription was observed, indicating that *H. pylori* screening and treatment strategy reduced endoscopy workload.

Joosen *et al.*<sup>37</sup> identified health outcomes and the costs and savings generated using an *H. pylori* test-and-treat strategy in 184 patients taking chronic acid suppressants. Significant symptom relief and improvements both in health benefits and cost savings were observed in the intervention group (test-and-treat strategy).

Madisch *et al.*<sup>38</sup> investigated the outcome of *H. pylori* eradication in staff members with uninvestigated chronic dyspepsia in a large factory in a prospective, open-label, controlled, workplace outcome study after 1 year of follow-up of dyspepsia, and quality of life. *H. pylori* status was assessed using the <sup>13</sup>C-urea breath test in 267 individuals with dyspepsia. At 12 months, 42% of responders showed complete relief of epigastric pain compared with 9.2% in the reference untreated group. Furthermore, disease-related absence from work, visits to family physicians, and antacid consumption decreased significantly in responders compared with reference subjects.

Farkkila *et al.*<sup>39</sup> performed a population-based study evaluating the effectiveness and safety of the test-and-treat strategy in real-life primary care settings. Dyspeptic patients (*N* = 1,552) aged between 25 and 60 years with no alarm symptoms were recruited. After screening with a <sup>13</sup>C-urea

breath test, *H. pylori*-positive patients received eradication therapy, whereas *H. pylori*-negative patients were treated with omeprazole. The authors concluded that, when applied in real life, the test-and-treat strategy failed to reduce the number of endoscopies, but significantly reduced peptic ulcer disease and improved dyspeptic symptoms and quality of life.

Gisbert *et al.*<sup>40</sup> prospectively evaluated the effectiveness of the test-and-treat strategy in a large group of dyspeptic patients in clinical practice. Of the initial 736 patients, 422 received eradication therapy and 314 symptomatic therapy. At 6 months, symptoms improved in 66% of patients (in 73% of patients receiving eradication therapy and in 54% of those receiving symptomatic therapy).

### DECISION ANALYSIS AND ECONOMIC MODELS

The gold-standard evidence of effectiveness for a clinical practice guideline is the RCT, although these studies have a limited ability to explore potential management strategies for a chronic disease where these interact over time. Modeling can be used to fill this gap. Decision analysis is a quantitative method for estimating the financial costs and clinical outcomes of alternative management strategies under conditions of uncertainty.<sup>41</sup> Decision analysis explicitly states alternative treatment choices, specifies the assumptions made in the analysis of the clinical problem, distinguishes between the probability of the occurrence of outcomes and the utilities associated with these outcomes, and provides quantitative estimates of each outcome. The most important factor in these models is the percentage of patients in the *H. pylori* test-and-treat group undergoing endoscopy during follow-up,<sup>32</sup> which could be as low as 10% or as high as 40%, with 30% being the best estimate.<sup>32</sup>

Data on cost-effectiveness of the test-and-treat strategy for *H. pylori* in dyspepsia have been gathered in several recent analyses and were reviewed by Di Caro *et al.*<sup>42</sup> We have updated these data (Table 3).<sup>32,43–61</sup> In summary, most of the decision analysis and economic models confirm test-and-treat to be better than prompt endoscopy.<sup>32,43,46,47,49,50,52,57,60</sup> The preference for the test-and-treat strategy over empirical antisecretory therapy is also suggested by most of the economic models (Table 3).<sup>43,45,47,51–53,55</sup>

Despite the usefulness of cost-effectiveness studies, decision analysis is based on numerous assumptions with regard to costs and benefits, and the probability of various medical states is extracted from the literature or estimated by expert opinion. All estimates reflect practice in a particular geographic area and cannot be extrapolated to other countries, and, therefore, decision analysis cannot and must not replace a good prospective design.<sup>62</sup>

Finally, two individual patient data meta-analyses compared test-and-treat with prompt endoscopy<sup>34</sup> and test-and-treat with empirical antisecretory therapy.<sup>30</sup> In the first meta-analysis, a small but statistically significant improvement in symptoms at 12 months was demonstrated for endoscopy (around 5% of patients),<sup>34</sup> but the cost was around €172 more per patient treated than test-and-treat. A cost effectiveness analysis demonstrated that at a realistic willingness to pay per symptom-free patient at 12 months (€1,070), prompt endoscopy was not cost effective for the

**Table 3** Cost-effectiveness studies evaluating the test-and-treat strategy

Author	Design	Strategies compared	Measured outcome	Conclusions
Barton <i>et al.</i> <sup>43</sup>	Decision analysis model	Test-and-treat vs. empirical acid suppression vs. initial endoscopy	Cost effectiveness, QALYs, and costs	Endoscopy was dominated at all ages by other strategies. PPI therapy was the most cost-effective strategy in 30-year olds with a low prevalence of <i>H. pylori</i> . In 60-year olds, <i>H. pylori</i> test-and-treat was the most cost-effective option
Chey <i>et al.</i> <sup>44</sup>	Decision analysis model	Antibody testing or testing to detect active <i>H. pylori</i> infection (active testing)	Appropriate and inappropriate treatment, cost per patient, incremental cost per unnecessary treatment avoided	Active testing led to a substantial reduction in unnecessary treatment for patients without active infection (antibody 23.7%; active, 1.4% patients) at an incremental cost of \$37 per patient
Chiba <i>et al.</i> <sup>45</sup>	Corrected alpha percentile bootstrap method	Test-and-treat vs. PPI	Cost per patient (direct and indirect costs)	The annual saving per patient, calculated for each increment of change in global overall symptoms, was CDN\$54
Fendrick <i>et al.</i> <sup>46</sup>	Decision analysis model	Two immediate endoscopy and three non-invasive diagnostic and treatment strategies	Cost per ulcer cured and cost per patient treated	The predicted costs per patient treated were as follows: (1) endoscopy and biopsy for <i>H. pylori</i> , \$1,584; (2) endoscopy without biopsy, \$1,375; (3) serology test for <i>H. pylori</i> , \$894; (4) empirical antisecretory therapy, \$952; and (5) empirical antisecretory and antibiotic therapy, \$818
Fendrick <i>et al.</i> <sup>47</sup>	Decision analysis model	Immediate endoscopy vs. empirical treatment with antisecretory therapy and serology testing for <i>H. pylori</i>	Cost per ulcer cured over a 1-year study period	The most cost-effective strategy was the test-and-treat strategy with \$4,481 cost per ulcer cured. The immediate endoscopy strategy resulted in a cost of \$8,045 per ulcer cured
García-Altés <i>et al.</i> <sup>48</sup>	Decision analysis model	Prompt endoscopy, score and scope, test and scope, test-and-treat, and empirical antisecretory treatment	Direct cost of each management strategy	Endoscopy was the most effective strategy for the management of dyspepsia. Incremental cost-effectiveness ratios showed that score and scope was the most cost-effective alternative (€483 per asymptomatic patient), followed by prompt endoscopy (€1,396)
Gee <i>et al.</i> <sup>49</sup>	Cost analysis in a breath test service	Test-and-treat vs. endoscopy	Cost of each management strategy	Referral to the breath test service costs £84.67 per dyspeptic patient; referral for endoscopy costs £98.35 per patient
Klok <i>et al.</i> <sup>50</sup>	Economical evaluation of a randomized clinical trial	Test-and-treat vs. prompt endoscopy	Health-care costs and quality of life	The total costs per patient were €511, with 0.037 QALY gained per patient in the test-and-treat group, and €748, with 0.032 QALY gained per patient in the endoscopy group. The test-and-treat strategy yielded cost savings and QALYs gained
Labadaum <i>et al.</i> <sup>51</sup>	Decision analysis model	Test-and-treat strategy vs. 1-month PPI	Health-care utilization (cost per patients treated)	The cost per patient treated differs little between the two non-invasive strategies analyzed (\$545 for the test-and-treat strategy vs. \$529 with PPI), while both achieve similar clinical outcomes.
Makris <i>et al.</i> <sup>52</sup>	Decision analysis model	Test-and-treat vs. endoscopy vs. empirical antisecretory treatment vs. empirical eradication treatment	Costs, effectiveness, and cost-effectiveness ratios	Endoscopy was not a cost-effective approach. Of the non-invasive test-and-treat strategies, using the breath test was the most effective and most costly strategy (\$8,238 per additional patient cured) compared with laboratory serology.
Marshall <i>et al.</i> <sup>53</sup>	Decision analysis model	Test-and-treat vs. empirical ranitidine	Direct medical costs and effectiveness in curing <i>H. pylori</i> -related ulcers	Breath test was more costly than either serology or ranitidine, but was the most effective strategy and required the fewest endoscopies. No strategy demonstrated dominance over another in the base case. The incremental cost-effectiveness ratio of serology vs. ranitidine was \$118/cure
Mason <i>et al.</i> <sup>54</sup>	Markov model from large randomized controlled trial data	Test-and-treat vs. placebo	Life years saved/population screening and intervention	Population test-and-treat would save more than £8,450,000 and 1,300 life-years per million people screened
Moayyedi <i>et al.</i> <sup>55</sup>	Markov model from systematic review of randomized controlled trials	Test-and-treat vs. 1 month of antacids	No. of months of symptom remission	Test-and-treat favored vs. antacids
Moayyedi <i>et al.</i> <sup>32</sup>	Decision analysis model	Test-and-treat vs. initial endoscopy	Costs effectiveness	<i>H. pylori</i> test-and-treat strategy is the most cost-effective method for managing dyspepsia, costing US \$134 per patient per year compared with US \$240 per patient per year for prompt endoscopy. The prompt endoscopy strategy only becomes cost effective in the unlikely scenario of endoscopy costing US\$160, the non-invasive test costing US\$80, and an <i>H. pylori</i> prevalence of <20%
Ofman <i>et al.</i> <sup>56</sup>	Decision analysis model	Test-and-treat vs. initial endoscopy in patients who are seropositive for <i>H. pylori</i>	Costs per patient	Initial endoscopy costs an average of \$1,276 per patient, whereas initial anti- <i>H. pylori</i> therapy costs \$820 per patient; the average saving is \$456 per patient treated. The financial effect of a 252% increase in the use of antibiotics for initial <i>H. pylori</i> therapy is more than offset by reducing the endoscopy workload by 53%
Silverstein <i>et al.</i> <sup>57</sup>	Decision analysis model	Test-and-treat vs. endoscopy vs. empirical antisecretory treatment	Direct medical charges in the first year after the onset of dyspepsia	Medical care charges were \$2,162.50 for initial endoscopy and \$2,122.60 for empirical therapy, a difference of 1.8%. Empirical therapy has lower costs than initial endoscopy when H2-receptor antagonists are used to prevent recurrence of dyspepsia. Initial non-invasive testing for <i>H. pylori</i> has lower costs than initial endoscopy if patients with dyspepsia and <i>H. pylori</i> infection receive antimicrobial therapy without endoscopy

Table 3 (Continued)

Author	Design	Strategies compared	Measured outcome	Conclusions
Sonnenberg <i>et al.</i> <sup>58,59</sup>	Decision analysis model	Serology testing vs. initial endoscopy	Cost-benefit relationship of serology testing for <i>H. pylori</i>	A response to eradication of <i>H. pylori</i> in 5–10% of all patients with non-ulcer dyspepsia would make screening and treatment for <i>H. pylori</i> a beneficial option, irrespective of any other potential benefits. If ulcer prevention were associated with a long-term benefit of \$4,000 or more and if the ulcer prevalence rate exceeded 10% of all dyspeptic patients, serology testing for <i>H. pylori</i> would also pay off
Spiegel <i>et al.</i> <sup>60</sup>	Decision analysis on a hypothetical cohort	Less invasive strategies (with either test-and-treat or PPI as first choice) vs. more invasive approaches	Proportion of symptom-free patients and QALY	Less invasive strategies (with either test-and-treat or PPI initial approach) preferred over more invasive strategies. Starting with test-and-treat had cost-effectiveness of \$1,714/QALY and \$2,007/symptom-free patient at 1 year
Vakil <i>et al.</i> <sup>61</sup>	Decision analysis model	Test-and-treat vs. endoscopy vs. empirical <i>H. pylori</i> treatment	Costs	Costs were very similar for both endoscopy (\$643) and serology (\$646) in the USA. In Finland, endoscopy (\$173) was less expensive than serology (\$192). Empirical treatment of children with dyspepsia was not cost effective in either country. Sensitivity analysis showed that when prevalence of infection was > 53%, empirical therapy was the optimal approach

Abbreviations: PPI, proton pump inhibitor; QALY, quality adjusted life year.

initial management of uninvestigated dyspepsia. In the second meta-analysis, no significant differences in symptoms or costs were demonstrated at 12 months of follow-up, although a trend was observed toward a net cost saving with test-and-treat; most of the saving was the result of a reduction in subsequent investigations.<sup>30</sup>

### CLINICAL PRACTICE GUIDELINES AND CONSENSUS CONFERENCE STATEMENTS

The 1994 NIH Consensus Panel Statement implicitly endorsed a strategy of documenting the presence of both ulcer and *H. pylori* infection before eradication therapy,<sup>63</sup> thus requiring increased invasive diagnostic testing before treatment could be prescribed. Moreover, at the 1998 conference of the American Digestive Health Initiative, the panel concluded that, based on available data, testing for and treating *H. pylori* infection had not been adequately investigated in terms of effectiveness, symptom relief, patient satisfaction, and cost.<sup>64</sup>

More recently, the 2004 guidelines from the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom also reflected this uncertainty, advocating the use of either test-and-treat or empirical acid suppression owing to a lack of available evidence demonstrating which is superior.<sup>65</sup>

Similarly, the 2005 guidelines of the American College of Gastroenterology<sup>66</sup> concluded that, in patients aged 55 years or younger with no alarm features, the clinician can choose between one of two approximately equivalent management options: (i) test-and-treat for *H. pylori* using a validated non-invasive test followed by a trial of acid suppression if eradication is successful but symptoms do not resolve; or (ii) an empirical trial of acid suppression with a PPI for 4–8 weeks. The test-and-treat option was shown to be preferable in populations with a moderate-to-high prevalence of *H. pylori* infection ( $\geq 10\%$ ), whereas the empirical PPI strategy is preferable in populations with a low prevalence.

The 2007 American College of Gastroenterology Guideline on the Management of *Helicobacter pylori* Infection stated that “the test-and-treat strategy for *H. pylori* infection is a proven management strategy for patients with uninvestigated dyspepsia who are under the age of 55 years and have no alarm features”.<sup>67</sup>

The use of the test-and-treat strategy was also advocated at the European Consensus Meeting held in Maastricht in 2005,<sup>68</sup> although this recommendation was classified as “advisable” by most of the participants, but not unanimously, and the strength of supporting evidence was classed as “equivocal”. More recently, at the last Maastricht Consensus Conference held in 2010, it was stated that “a test-and-treat strategy is indicated for uninvestigated dyspepsia in populations where the *H. pylori* prevalence is high (> 20%)”.<sup>69</sup> On this occasion, the evidence level was classified as “A” (the highest) and the strength of the recommendation as “1a” (again, the highest).

### AGE THRESHOLD AT WHICH TEST-AND-TREAT IS APPLIED

Although non-invasive *H. pylori* testing seems increasingly preferable to endoscopy when determining the management of younger patients presenting with dyspepsia, the possibility that this approach may result in missing potentially curable malignancy gives cause for concern, and the age at which endoscopy is advisable to exclude underlying upper gastrointestinal malignancy remains uncertain.<sup>70</sup> In fact, as no randomized controlled data support or refute a specific age cutoff, this arbitrary assignment remains based on expert opinion. The age threshold at which available management guidelines recommend prompt endoscopy for uninvestigated dyspepsia varies from 45 to 55 years in Western Europe and North America (Tables 1 and 2). This is the age at which the incidence of upper gastrointestinal malignancy begins to increase significantly,<sup>71,72</sup> although in some Eastern European and Asian countries a lower threshold is used, owing to the higher prevalence of gastric cancer.<sup>73</sup> Thus, the age cutoff

point depends on local incidence of gastric cancer in different age groups.<sup>69</sup>

Initially, the American Gastroenterology Association, the American College of Gastroenterology, the American Society for Gastrointestinal Endoscopy, the British Society of Gastroenterology, and the European Society of Primary Care Gastroenterology recommended endoscopy for patients aged over 45 years.<sup>74–77</sup> More recently, a test-and-treat strategy with an age threshold set at 50 years has been validated in primary care.<sup>78,79</sup> Accordingly, some authors and the Canadian Dyspepsia Working Group have recommended setting the age threshold at 50 years.<sup>80–84</sup>

Gillen and McColl<sup>85</sup> assessed whether concern over occult malignancy is valid in patients aged <55 years presenting with uncomplicated dyspepsia by reviewing the case notes of patients aged <55 years who had presented with esophageal or gastric cancer. Upper gastrointestinal malignancy was extremely rare in patients <55 years presenting with uncomplicated dyspepsia and, when found, was usually incurable. Consequently, this study suggests that concern about missing underlying curable malignancy is not a valid reason for recommending endoscopy in this population. Similar results have been obtained by other authors.<sup>20,71,86</sup>

The updated British Society of Gastroenterology guidelines suggested an age threshold of 55 years for endoscopy.<sup>87</sup> Similarly, the Guidelines developed under the auspices of the American College of Gastroenterology<sup>66</sup> recommended setting the cutoff point at 55 years, and the American College of Gastroenterology Guideline on the Management of *Helicobacter pylori* Infection stated that “the test-and-treat strategy for *H. pylori* infection is a proven management strategy for patients with uninvestigated dyspepsia who are under the age of 55 years and have no alarm features”.<sup>67</sup>

Finally, a recent study showed that the test-and-treat strategy turned out to be a safe method for managing uninvestigated dyspepsia in primary health care, even when applied in patients aged up to 60 years of age.<sup>39</sup>

Some observations suggest that age appears to be a poor predictor of underlying pathology.<sup>88</sup> In this respect, age was not even considered in two relevant studies evaluating the test-and-treat strategy, while only the presence of alarm symptoms was taken into account.<sup>19,45</sup> It was noteworthy that none of the patients included in the test-and-treat strategy in these studies was diagnosed with cancer during follow-up.<sup>19,45</sup> Accordingly, the NICE in the United Kingdom issued a guideline recommending that all dyspeptic patients without alarm symptoms, irrespective of age, should be managed initially without endoscopy (but with PPI therapy for 1 month).<sup>87</sup>

In summary, although convincing data supporting a specific age cutoff for endoscopy are lacking, and therefore the decision remains somewhat arbitrary, setting the age threshold at 50 or even 55 years (rather than 45 years) seems reasonable in the USA and in most Western European countries, because cancer is rare in younger patients.<sup>89</sup> However, the age at which endoscopy is required in patients with new-onset dyspepsia depends on geographic region and patient population.<sup>82</sup>

## COST AND AVAILABILITY OF ENDOSCOPIC EXAMINATION

The cost of endoscopy ranges widely from one country to another, thus considerably affecting the cost–benefit relationship of the test-and-treat strategy. By using sensitivity analysis, decision analyses can vary assumptions about probabilities and utilities and determine their impact on outcomes. Thus, for example, Silverstein *et al.*<sup>57</sup> evaluated initial endoscopy and testing for *H. pylori* in the management of dyspeptic patients. The analysis favored non-invasive strategies when the estimated cost of endoscopy was US\$500; however, if endoscopy cost <\$277, initial endoscopy was the least costly strategy. Fendrick *et al.*<sup>46</sup> compared two invasive and three initially non-invasive strategies and concluded that an initial non-invasive strategy including *H. pylori* eradication therapy in infected patients was the most cost-effective approach; however, when the cost of endoscopy was <\$500, the strategies were equally cost-effective. Furthermore, the cost of endoscopy is not uniform around the world; in the United States it was particularly high but is decreasing, and many models suggest that when the procedure costs <\$500, early endoscopy may become a cost-effective alternative. When the cost is <\$200, initial endoscopy becomes the intervention of choice in all of the models.<sup>84</sup>

Use of endoscopy is also affected by availability; thus, empirical treatment of *H. pylori* infection is probably preferable when access to prompt upper endoscopy is limited. For example, bearing in mind the limited health resources in the Asia-Pacific region, it would be prudent to adopt an *H. pylori* test-and-treat strategy as the initial management approach for young Southeast Asian patients.<sup>23</sup> In addition, long waiting lists may decrease the diagnostic efficacy of endoscopy, thus favoring non-invasive strategies.

## PREVALENCE OF *H. PYLORI* INFECTION IN PATIENTS WITH DYSPEPSIA

The prevalence of the infection changes the predictive value of the diagnostic method.<sup>90</sup> When infection is frequent, the pretest probability of *H. pylori* infection increases; for example, in developing countries or in patients with *H. pylori*-related diseases such as duodenal ulcer, the predictive value of a negative diagnostic test markedly decreases and, consequently, the number of false-negative results increases. In other words, the higher the baseline prevalence of *H. pylori*, the less confident one should be about a negative test result.<sup>90</sup> Furthermore, in populations in which *H. pylori* is highly prevalent, some infected patients with a gastroduodenal ulcer will not receive eradication therapy because of false-negative results. False-positive results in these settings are exceedingly rare, and a positive result does not need confirmation and mandates treatment. On the other hand, the lower the prevalence of *H. pylori* (for example, in developed countries), the lower the positive predictive value (i.e., more false-positive results); test-and-treat must be used cautiously in low-prevalence populations, as non-invasive tests become less accurate in this setting.<sup>91</sup> The main problem in this case is that many uninfected patients will be inadequately treated with antibiotics.



Where local prevalence of *H. pylori* is known to exceed 10%<sup>92</sup> or 20%,<sup>68</sup> test-and-treat is recommended.<sup>33,69</sup> In contrast, PPI treatment was consistently less costly than test-and-treat when the prevalence of *H. pylori* was <10–20%.<sup>51</sup> Therefore, in all settings, it seems important to consider the findings of epidemiologic studies evaluating the prevalence of *H. pylori* in patients with uninvestigated dyspepsia. It has been suggested that in many parts of Europe and North America, the prevalence of *H. pylori* infection and of peptic ulcer disease is declining to a point that may soon make test-and-treat-based strategies irrelevant.<sup>93–95</sup> Although this finding may be true, it is based mainly on theoretical analyses and needs support from real-life data. Multinational clinical trials performed in areas with different *H. pylori* prevalence rates, but comparing identical strategies using identical protocols, would provide important data.<sup>95</sup>

In summary, the test-and-treat option is preferable in populations of dyspeptic patients with a moderate-to-high prevalence of *H. pylori* infection ( $\geq 10$ –20%), whereas the empirical PPI strategy may be preferable in low-prevalence populations.<sup>33,66,69,92</sup>

#### TYPE OF DIAGNOSTIC METHODS TO DETECT *H. PYLORI* INFECTION

The three non-invasive methods that can be used for the test-and-treat strategy are serology, the <sup>13</sup>C-urea breath test, and the stool antigen test. Although some serology tests have been reported to have high sensitivity and specificity, blood tests may perform differently in different geographic locations, probably because of variation in strains, suggesting that only locally validated tests should be used.<sup>96,97</sup> In general, serology should be considered less accurate than <sup>13</sup>C-urea breath test and monoclonal stool antigen tests.<sup>69,96–102</sup>

On the other hand, rapid (“office”) serology tests using whole blood could facilitate application of the test-and-treat strategy in general practice. However, these tests have not yet been approved,<sup>68</sup> as the sensitivities and specificities observed to date have generally been disappointing.<sup>25</sup> Duggan *et al.*<sup>103</sup> evaluated the performance of a near-patient test for *H. pylori* infection in primary care, and found that the sensitivity of the FlexSure test was <70%; thus, about one-third of infections were not detected. In another study,<sup>24</sup> the same authors validated the near-patient serology test previously used in their trial and reported 69% sensitivity and 98% specificity; again, this low sensitivity may mean that about one-third of *H. pylori*-infected dyspeptic patients would have gone undetected and many peptic ulcers would have been missed.

Given the diagnostic performance limitations of serology tests and the clinical and economic consequences of applying suboptimal blood tests for *H. pylori*, some authors have questioned the rationale of using them in general practice, suggesting that the <sup>13</sup>C-urea breath test is a better option.<sup>104</sup> A recent economic study suggests that the test-and-treat strategy using the <sup>13</sup>C-urea breath test is more cost effective than test-and-treat using serology.<sup>105</sup>

Stool tests may also be valid as non-invasive tests.<sup>69</sup> McNulty *et al.*<sup>106</sup> explored the views of primary care about introducing the *H. pylori* test-and-treat strategy and found that

staff preferred stool tests to breath tests, as they impacted less on practice budget and time. On the other hand, stool antigen testing may be somewhat less acceptable to patients.

During the last few years, new formats of the stool antigen test using monoclonal antibodies ensure constant antigen composition and, therefore, similar diagnostic reliability in the different kits of the same test. For this reason, monoclonal tests are far more reliable than tests based on polyclonal antibodies, where antibody composition could change from one kit to another. The two formats available are: (1) laboratory tests (enzyme-linked immunosorbent assay), and (2) rapid office tests using an immunochromatographic technique. A meta-analysis of 22 studies including 2,499 patients showed that laboratory stool antigen tests based on monoclonal antibodies are highly accurate in both initial and post-treatment diagnosis of *H. pylori*.<sup>98</sup> In contrast, the rapid office tests were less accurate.<sup>107,108</sup> Therefore, when a stool antigen test has to be used, the recommendation is for an enzyme-linked immunosorbent assay format with a monoclonal antibody as the reagent.<sup>69</sup>

A disadvantage of both the breath test and stool antigen test is that, in contrast with serology, patients must stop taking PPIs for at least 2 weeks before testing.<sup>14,109</sup> Furthermore, antibiotics must be stopped at least 4 weeks before.

In summary, as part of the test-and-treat strategy, the <sup>13</sup>C-urea breath test remains the best approach to diagnosis of *H. pylori* infection, as it is highly accurate and easy to perform.<sup>99</sup> Stool antigen testing may be somewhat less acceptable to patients in some cultures but is equally valid with high sensitivity and specificity provided a monoclonal antibody-based enzyme-linked immunosorbent assay is used.<sup>110</sup>

#### PROPORTION OF *H. PYLORI*-POSITIVE PATIENTS WHO HAVE OR WHO WILL DEVELOP PEPTIC ULCER, AND PROPORTION OF ULCERS ATTRIBUTABLE TO *H. PYLORI*

Patients with peptic ulcer disease represent the population that most clearly benefits from eradication of *H. pylori*, as eradication of the organism is associated with a high ulcer cure rate, a very low ulcer recurrence rate, a protective effect against complications of ulcer, and a reduction in costs.<sup>111,112</sup> Test-and-treat leads to resolution of symptoms in <50% of uninvestigated infected dyspepsia patients, the poor results being related to the relatively small percentage of patients with peptic ulcer disease and to the small benefit of eradication of *H. pylori* in patients with functional dyspepsia (see next section).<sup>113</sup> According to sensitivity analyses, test-and-treat is favored in geographical areas where the prevalence of ulcer or *H. pylori* infection, which usually occur simultaneously, are high, whereas empirical antisecretory therapy is favored when prevalence rates are low.

Sonnenberg *et al.*<sup>58</sup> analyzed the outcome of serology testing for *H. pylori* in dyspepsia using a decision analysis and found that the cost–benefit relationship of this approach was considerably influenced by the prevalence rate of peptic ulcer in *H. pylori*-positive patients; thus, if the prevalence of ulcer exceeded 10% of all dyspeptic patients, serology testing for

*H. pylori* would be cost effective. Similarly, other authors have reported that when the prevalence of peptic ulcer is low (<12%), empirical antisecretory therapy would be the most cost-effective strategy.<sup>114</sup> The proportion of *H. pylori*-positive individuals with an active ulcer at the time of endoscopy remains unclear, but published figures range from <5% to >30%.<sup>115–122</sup> In patients with uninvestigated dyspepsia, the prevalence of peptic ulcer is around 20%, that is, about one-third of *H. pylori*-positive dyspeptic patients,<sup>123</sup> again showing that the test-and-treat strategy remains cost effective in most settings. With regard to the number of *H. pylori*-positive asymptomatic individuals who will develop an ulcer, the infection has been described as a risk factor for the development of peptic ulcer.<sup>122,124,125</sup> Thus, the estimated lifetime risk for the development of peptic ulcer in asymptomatic patients infected by *H. pylori* ranges from 10 to 20%.<sup>126</sup>

*H. pylori* infection rates in patients with peptic ulcer disease are still very high, although they may be lower than in previous estimations.<sup>127</sup> A recent systematic review of studies published during the last 10 years including 16,080 patients calculated a mean prevalence of *H. pylori* infection of “only” 81% in duodenal ulcer disease; this figure was even lower (77%) when only the last 5 years were analyzed. In truly *H. pylori*-negative patients, the most common single cause of ulcer is, by far, the use of non-steroidal anti-inflammatory drugs (patients taking non-steroidal anti-inflammatory drugs are excluded from the test-and-treat strategy, as endoscopy is generally recommended). Ulcers not associated with *H. pylori*, non-steroidal anti-inflammatory drugs, or other obvious causes should, for the present, be viewed as idiopathic. However, true idiopathic duodenal ulcer disease is exceptional.<sup>127</sup>

### ROLE OF *H. PYLORI* IN THE DEVELOPMENT OF GASTRIC CANCER

The risk of gastric adenocarcinoma attributable to *H. pylori* has been estimated to be between 35 and 60%<sup>128–134</sup>; in addition, *H. pylori* infection increases sixfold the risk of having this cancer.<sup>135</sup> Several years ago, the WHO classified the relationship between *H. pylori* and gastric adenocarcinoma as category I, which implies that the microorganism is considered a proved carcinogenic factor.<sup>136</sup> Further evidence linking gastric adenocarcinoma to *H. pylori* infection has accumulated since then. Specifically, recent studies have shown that strains with increased CagA activity are associated with a relevant high risk of gastric cancer.<sup>137,138</sup> Different harmful capabilities of the individual *H. pylori* strains may explain why only a proportion of infected patients develop malignancy.<sup>139–143</sup> It is now widely accepted that early eradication of *H. pylori* (before mucosal preneoplastic changes such as gastric atrophy or, mainly, intestinal metaplasia develop) is effective in preventing gastric adenocarcinoma; in addition, screening and treatment of *H. pylori* infection is strongly recommended in high-risk populations.<sup>144</sup>

*H. pylori* is also considered the main causal factor of low-grade mucosa-associated lymphoid tissue lymphomas of the stomach.<sup>145,146</sup> As is the case with gastric adenocarcinoma, only a reduced proportion of infected patients will

develop mucosa-associated lymphoid tissue lymphoma; therefore, it can be deduced that factors other than the organism have an important role in this disease.<sup>145–148</sup> Nevertheless, although *H. pylori* could be responsible for approximately two-thirds of gastric lymphomas,<sup>149</sup> it is evident that *H. pylori* is—again—not sufficient for the development of mucosa-associated lymphoid tissue lymphoma. However, it is probably the most relevant and the most easily avoidable risk factor (by eradication).

Widespread population screening and eradication of *H. pylori* has the potential to reduce the incidence of gastric cancer (both adenocarcinoma and lymphoma), although further large-scale studies are warranted.<sup>150,151</sup> In addition to curing symptoms, test-and-treat strategies in young patients with uninvestigated dyspepsia are also likely to decrease the risk of gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma and aid the management of these important public health issues.<sup>150</sup>

### ROLE OF *H. PYLORI* IN FUNCTIONAL DYSPEPSIA

Functional dyspepsia is defined according to the Rome III criteria as the presence of symptoms thought to originate in the gastroduodenal region, in the absence of any organic, systemic, or metabolic disease that is likely to explain the symptoms.<sup>15</sup> This implies that *H. pylori* infection needs to be excluded (and/or treated) before a diagnosis of functional dyspepsia can be reached.<sup>152</sup>

The potential role of *H. pylori* in functional dyspepsia is very relevant, as most patients will be included in this symptomatic group.<sup>115,116</sup> No relationship has been established between *H. pylori* and functional dyspepsia<sup>153–155</sup> for the following reasons: (i) a higher prevalence of the infection in functional dyspepsia patients has not been universally reported; (ii) a close correlation between *H. pylori* status and a particular symptomatic pattern has not been observed; (iii) the organism does not seem to induce changes in gastrointestinal motility; and, most importantly, (iv) although some studies have shown an improvement in symptoms after eradication of *H. pylori*,<sup>156</sup> others have not.<sup>157</sup>

However, although *H. pylori* does not seem to be the cause of functional dyspepsia, most studies and several meta-analyses show that a small proportion of patients with functional dyspepsia experience a long-term improvement in their dyspeptic symptoms after cure of *H. pylori* infection. As the course of peptic ulcer disease alternates between flares and remission periods, and endoscopy between flares could be normal, it may well be that eradication of *H. pylori* benefits functional dyspepsia by curing the small proportion of patients with peptic ulcer disease who go undetected during the diagnostic work-up. To date, several meta-analyses and systematic reviews examining the effect of eradicating *H. pylori* on improvement in dyspeptic symptoms have been published.<sup>55,157–160</sup> The number-needed-to-treat (to cure one dyspeptic patient with eradication therapy) has been calculated to be 13 [ref. 161]. Although this effect is modest, it is important to highlight that the benefits of eradicating *H. pylori* seem to persist at least 1 year after treatment; therefore, this approach is cost effective in patients with functional dyspepsia and *H. pylori* infection.<sup>55</sup>

Eradication is cost effective despite the low number of responders, because treatment alternatives are even poorer. In this sense, although the number-needed-to-treat for PPI therapy (the other effective treatment for functional dyspepsia) is better (about nine), these drugs are limited by their very transient effect, and symptoms tend to recur early after treatment.<sup>162</sup>

Sonnenberg *et al.*<sup>58</sup> suggested that the benefit to patients with functional dyspepsia after eradication of *H. pylori* may be a key factor in support of test-and-treat. The authors analyzed the outcome of serology testing for *H. pylori* in dyspepsia using a decision tree and found that, if the response rate of functional dyspepsia to *H. pylori* eradication is >5–10% of all patients, the test-and-treat strategy becomes highly cost effective, even if we do not take into account any of the other potential benefits of the test-and-treat strategy.

### EFFICACY, COST, AND ADVERSE EFFECTS OF *H. PYLORI* ERADICATION THERAPY

The efficacy, cost, and adverse effects of eradication therapy must be taken into account, as treatment will be administered to a considerable number of patients if the test-and-treat strategy is followed. To date, the most widely recommended treatment for the eradication of *H. pylori* in international guidelines is the so-called standard triple therapy, which combines two antibiotics (clarithromycin plus amoxicillin or metronidazole) with a PPI for 7–14 days. However, since the micro-organism was discovered, the eradication rate has fallen considerably with this regimen,<sup>163</sup> thus increasing the need for alternative treatment strategies (e.g., bismuth-containing quadruple therapy<sup>164</sup> and non-bismuth quadruple sequential and concomitant regimens).<sup>165,166</sup> The cost-benefit ratio of test-and-treat strategies should increase if eradication therapies reach close to 100% efficacy, costs decrease, and the safety profile improves.

Adverse effects associated with eradication regimens are not problematic in clinical practice, as tolerance of the above-mentioned therapies is rather good and severe side effects are extremely rare. Nevertheless, even if the incidence of adverse effects is very low, the prescription of eradication therapy for a large number of patients will be followed by a significant number of antibiotic-related adverse effects.<sup>167</sup>

Furthermore, the emergence of resistance by *H. pylori* will complicate the test-and-treat strategy.<sup>167</sup> Resistance to metronidazole and to clarithromycin is already a relevant therapeutic problem,<sup>168,169</sup> and, more importantly, resistance rates (especially to clarithromycin) seem to be increasing in parallel with the progressive increase in antibiotic prescription.<sup>168–170</sup> In this sense, some authors fear that test-and-treat strategies will widen the problem of community-acquired antibiotic resistance, even against micro-organisms other than *H. pylori*. However, the estimated level of inappropriate antibiotic prescription in primary care is extremely high (1.43 prescriptions per person per year). In this scenario, a test-and-treat strategy for uninvestigated dyspepsia patients—apart from being a correct indication for antibiotic therapy—will have a negligible impact on community antimicrobial resistance rates.<sup>32,171</sup>

### RISK OF MISSING SERIOUS DISEASES

Although delayed diagnosis of gastric cancer resulting from an empirical trial of therapy or the test-and-treat strategy for *H. pylori* has not been shown to adversely affect outcomes, concern remains.<sup>172–174</sup> The risk will be minimized by restricting this strategy to young patients (see corresponding section for the recommended age threshold) without alarm symptoms.<sup>175</sup> In this respect, upper gastrointestinal malignancy is extremely rare in patients <55 years presenting with uncomplicated dyspepsia; and when found, it is usually incurable.<sup>85</sup> Furthermore, only a small proportion of young gastric cancer patients present without alarm symptoms and, as dyspepsia associated with gastric cancer is less responsive to empirical therapy, such patients would be investigated eventually, as their symptoms fail to respond.<sup>176</sup> Finally, despite the delay in diagnosis, patients with gastric cancer and no alarm symptoms have a better outcome than those with alarm symptoms. Thus, the diagnostic delay in patients without alarm symptoms does not seem to affect survival.<sup>177</sup>

The test-and-treat strategy has been compared with prompt endoscopy in eight RCTs including 1,438 patients.<sup>17–24</sup> Three upper gastrointestinal malignancies were detected at subsequent endoscopy in the test-and-treat arms of these trials, and three in the prompt endoscopy arms, with no significant diagnostic delay as a result of assignment to a test-and-treat strategy in any of these patients.<sup>33</sup>

Obviously, the presence of alarm symptoms should prompt investigation to rule out severe disease.<sup>178,179</sup> However, alarm symptoms appear to be a poor predictor of underlying pathology.<sup>88,180</sup> A recent systematic review and meta-analysis that evaluated the accuracy of alarm features in the diagnosis of upper gastrointestinal malignancy, demonstrated that the positive predictive value of these symptoms was disappointingly low. Therefore, more efficient ways of predicting which individuals with dyspepsia are likely to have gastroesophageal malignancy are required.<sup>72</sup>

Finally, management of dyspepsia might differ between countries.<sup>181,182</sup> The incidence of upper gastrointestinal malignancy is significantly higher overall in China than in Western countries.<sup>181</sup> For example, Li *et al.*<sup>181</sup> showed that if the *H. pylori* test-and-treat strategy were used in dyspeptic patients under the age of 45 years without alarm symptoms in the Shanghai region, then, based on the results of a recent study, 13 of the 162 gastric cancers found in a population of 14,101 patients undergoing endoscopy would be missed. The authors concluded that the test-and-treat strategy is not suitable for the management of patients with uninvestigated dyspepsia in Shanghai, and that for most dyspeptic patients living in this area, prompt endoscopy should be recommended as the first-line initial management option.<sup>181,183</sup>

### ENDOSCOPY OR EMPIRICAL PPI AFTER FAILURE OF TEST-AND-TREAT

The cost-effectiveness of test-and-treat may be further improved by treating non-responding symptoms (despite *H. pylori* eradication) with an empirical trial of PPI therapy, rather than by immediately referring patients for

endoscopy.<sup>84</sup> This strategy has been recommended by international guidelines.<sup>15,66</sup> A recent decision analysis model found that a strategy consisting of initial test-and-treat for *H. pylori* followed by empirical PPI therapy in non-responders and endoscopy only for patients with persistent dyspeptic symptoms may be more cost effective than test-and-treat or empirical antisecretory therapy alone.<sup>60</sup> In summary, when treatment fails despite eradication of *H. pylori*, a trial with PPI therapy is a reasonable next step. However, head-to-head management trials will be needed to confirm these conclusions.

## PATIENT SATISFACTION

Patient satisfaction has not been incorporated into the analysis of the test-and-treat strategy, as it is a difficult concept to model. Many dyspeptic patients presenting for medical care have a fear of serious disease and malignancy.<sup>184</sup> In addition, they are more anxious than non-presenters with similar complaints.<sup>185</sup> A completely normal endoscopy could relieve some patients of their anxiety. Perhaps because of this, patients undergoing endoscopy were more satisfied with the investigation than patients randomized to the *H. pylori* test-and-treat strategy.<sup>32</sup> Endoscopy is technically more complicated and expensive, and patients may therefore perceive endoscopy as being "better", even if there is no improvement in quality of life or dyspepsia compared with simpler investigation strategies.<sup>32</sup> As accurately noted by Moayyedi,<sup>32</sup> this is analogous to consumers preferring an expensively packaged product to an identical but less well marketed item.

## FOLLOW-UP TIME

The long-term effect of the test-and-treat strategy is unknown. In fact, RCTs and simulation models have compared strategies with a 1-year perspective, although the long-term consequences are unknown. In particular, concerns have arisen over the safety and possible high costs of ongoing long-term PPI therapy in patients receiving empirical PPIs.<sup>186</sup> Furthermore, postponing upper gastrointestinal endoscopy in the short term has not been shown to lead to cancellation of the test in the long term. Patients who initially respond to testing-guided management strategies with recurrence of symptoms might eventually undergo endoscopy, long after the initial follow-up period has ended.<sup>187</sup>

As follow-up in most studies comparing prompt endoscopy with test-and-treat was limited to 12 months, it is uncertain whether the observed economic benefit of preferring test-and-treat is sustained in the long term. Fortunately, some studies have performed follow-up longer than 12 months. For example, Slade *et al.*<sup>188</sup> initially reported that endoscopy can be avoided after performing the test-and-treat strategy and that this approach reduces endoscopic workload by 74%. More recently, in a 2-year long-term follow-up study of 232 participants from their previous trial, the severity of dyspepsia symptoms was lower than the initial scores at recruitment.<sup>189</sup> Thus, 66% of the original participants were able to avoid endoscopy.

Laheij *et al.*<sup>187</sup> compared the long-term results of empirical treatment followed by the *H. pylori* test-and-treat strategy

(treat-and-test group) with the results of prompt endoscopy followed by targeted medical treatment (endoscopy group). The authors provided long-term follow-up data from a previously published RCT. At least 6 years after randomization, no differences were observed in symptom prevalence and quality of life between the groups. Furthermore, patients initially managed with a test-and-treat strategy required fewer additional diagnostic procedures and less long-term PPI treatment than those initially randomized to endoscopy. Thus, test-and-treat did not lead to additional diagnostic testing or use of medication when compared with prompt endoscopy. In particular, 6 years after randomization, 60% of patients who would normally have been referred for diagnostic testing but were instead managed by the treat-and-test strategy had not undergone upper gastrointestinal endoscopy.<sup>187</sup>

The study including the largest follow-up up to date was performed by Lassen *et al.*<sup>26</sup> A total of 500 patients presenting in primary care with dyspepsia were randomized to management by *H. pylori* testing plus eradication therapy ( $n=250$ ) or endoscopy plus eradication of *H. pylori* only in patients with duodenal or gastric ulcers ( $n=250$ ). Symptoms, quality of life, and patient satisfaction were recorded over a 3-month period a median of 6.7 years after randomization. The authors reported that the lower rates of endoscopy and fewer prescriptions for acid suppression therapy observed at 12 months in those managed with a test-and-treat strategy persisted. Rates of dyspepsia remained comparable between the two arms of the trial, but the test-and-treat patient arm required less PPI maintenance therapy.<sup>26</sup>

## SETTING OF TESTING (HOSPITALS OR GENERAL PRACTICE)

In theory, a test-and-treat strategy is best used in primary care as patients initially present to their general practitioner with dyspepsia. In addition, as many patients referred to hospital expect to undergo endoscopy, it is difficult to convince them that the procedure is not necessary. However, some of the studies on *H. pylori* management strategies analyze patients in hospital centers. Although the exact reasons leading patients to be referred to hospital are poorly understood, it has been suggested that patients referred to hospital may not represent the dyspeptic population seen in primary care.<sup>190–192</sup> If, for example, *H. pylori* infection or peptic ulcer disease was less common in subjects not referred, the cost-effectiveness of the test-and-treat strategy would be less favorable in primary care.<sup>190</sup> Nevertheless, although patients should ideally be recruited from primary care, as the trial results will be applied to this population,<sup>32</sup> no published data support that uninvestigated dyspepsia patients behave differently in specialized or primary care. In fact, referral might reflect more the health-care system structure than true differences in patients' characteristics.

On the other hand, some authors have observed that the results of a test-and-scope strategy based on age and *H. pylori* status obtained from RCTs performed better in a referral center than in non-referral hospitals.<sup>193</sup> Mahadeva *et al.*<sup>194</sup> showed that a test-and-treat policy did not reduce endoscopy workload in a district (non-referral) hospital, suggesting that results from centers with interest in *H. pylori*

research cannot necessarily be extrapolated to the vast majority (non-referral centers or general practice).

Finally, most published results were obtained from RCTs, and the results in carefully selected clinical trials may not reflect results of practice in the real world. Unfortunately, reports of clinical series evaluating the test-and-treat strategy in clinical practice—in contrast to RCTs—are very scarce. One exception is the TETRA study, which was performed in the outpatient setting, following the clinical practice of gastroenterologists in Spain.<sup>40</sup> This large prospective study showed that test-and-treat was effective and safe for management of dyspeptic patients in clinical practice.

## IMPLEMENTATION OF GUIDELINES IN CLINICAL PRACTICE

The impact of practice guidelines on patient care ultimately depends on their implementation by clinicians.<sup>195</sup> Authors who explored the introduction of test-and-treat from the perspective of primary care found that primary care health staff reported that the major barrier to the introduction of NICE test-and-treat guidance for patients with dyspepsia was the time taken to give patients information on testing, test results, and treatment and the impact on nurses' time.<sup>106</sup>

Numerous strategies have been used to promote integration of clinical research findings into clinical practice, with passive dissemination of information generally proving ineffective.<sup>196,197</sup> In contrast, educational outreach visits to clinicians and combinations of two or more interventions could increase the likelihood of affecting practice patterns.<sup>196</sup> Some authors have demonstrated that the combination of an educational session led by gastroenterology subspecialists and the availability of office-based *H. pylori* testing can increase acceptance of the test-and-treat strategy by primary care providers.<sup>79</sup> Thus, patients who received this test-and-treat intervention were less likely to receive repeated antisecretory medication prescriptions than controls receiving usual care (passive dissemination of a practice guideline).<sup>79</sup>

## CONCLUSIONS

Dyspepsia is a very frequent and usually chronic condition, accounting for almost 5% of all primary care consultations.<sup>42</sup> The available management strategies for individuals with uninvestigated dyspepsia include prompt endoscopy, empirical antisecretory therapy, and the test-and-treat strategy for *H. pylori*. Although each of the three management options of uninvestigated dyspepsia have advantages and disadvantages, it is widely accepted that endoscopy should be reserved for patients with symptom onset after 45–55 years of age, those who have alarm features, and those whose empirical antisecretory therapy or test-and-treat strategy fails.

The test-and-treat strategy will cure most cases of underlying peptic ulcer disease and prevent most potential cases of gastroduodenal disease. In addition, a minority of infected patients with functional dyspepsia will gain symptomatic benefit.<sup>15</sup> Future studies should be able to identify the key epidemiological and patient-related features that would enable us to stratify dyspeptic patients accor-

ding to their likelihood of improving after treatment of infection by *H. pylori*.<sup>42</sup> In the meantime, the test-and-treat strategy is being reinforced by the accumulating data that support the increasingly accepted idea that “the only good *Helicobacter pylori* is a dead *Helicobacter pylori*”.<sup>198</sup>

Several prospective studies and decision analyses support the use of the test-and-treat strategy, although we must be cautious when extrapolating the results from one area to another. Many factors determine whether this strategy is appropriate in each particular geographic area.

As recently pointed out, over the past 20 years we have seen *H. pylori* infection transform the way in which we treat patients with dyspepsia; we are now facing the challenge of allowing it to transform the way in which we investigate dyspepsia, in particular the use of endoscopy.<sup>199</sup>

## CONFLICT OF INTEREST

**Guarantor of the article:** Javier P. Gisbert, MD, PhD.

**Specific author contributions:** J.P. Gisbert had the original idea, performed the search strategy for identification of studies, and wrote the manuscript. X. Calvet reviewed the manuscript and did relevant suggestions.

**Financial support:** None.

**Potential competing interests:** None.

**Acknowledgements.** CIBEREHD is funded by the Instituto de Salud Carlos III. This study was not funded by any Pharmaceutical Company.

## Study Highlights

### WHAT IS CURRENT KNOWLEDGE

- ✔ Dyspepsia is a major health problem.
- ✔ The available management strategies for individuals with uninvestigated dyspepsia include prompt endoscopy, empirical antisecretory therapy, and the test-and-treat strategy for *H. pylori*.
- ✔ The initial approach to diagnosis of dyspepsia has traditionally been oral endoscopy.
- ✔ Other diagnostic strategies based on the response to empirical (antisecretory) treatment have been used, although none has proved to be definitively useful.
- ✔ Recently proposed strategies are based on the non-invasive diagnosis of *H. pylori* infection, for example, the test-and-treat strategy.

### WHAT IS NEW HERE

- ✔ The test-and-treat strategy will cure most cases of underlying peptic ulcer disease and prevent most potential cases of gastroduodenal disease.
- ✔ In addition, a minority of infected patients with functional dyspepsia will gain symptomatic benefit.
- ✔ The test-and-treat strategy is being reinforced by the accumulating data that support the increasingly accepted idea that “the only good *H. pylori* is a dead *H. pylori*”.
- ✔ Several prospective studies and decision analyses support the use of the test-and-treat strategy.

1. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. *BMJ* 1989; **298**: 30–32.
2. Jones RH, Lydeard SE, Hobbs FD *et al.* Dyspepsia in England and Scotland. *Gut* 1990; **31**: 401–405.
3. Drossman DA, Li Z, Andruzzi E *et al.* U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Dig Dis Sci* 1993; **38**: 1569–1580.
4. Talley NJ, Zinsmeister AR, Schleck CD *et al.* Dyspepsia and dyspepsia subgroups: a population-based study. *Gastroenterology* 1992; **102**(4 Pt 1): 1259–1268.
5. Agreus L, Svardssudd K, Nyren O *et al.* Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. *Gastroenterology* 1995; **109**: 671–680.
6. Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. *Scand J Gastroenterol Suppl* 1991; **182**: 17–24.
7. Rubin GP, Contractor B, Bramble MG. The use of long-term acid-suppression therapy. *Br J Clin Pract* 1995; **49**: 119–120.
8. Talley NJ, Weaver AL, Zinsmeister AR *et al.* Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. *Am J Epidemiol* 1992; **136**: 165–177.
9. Talley NJ, McNeil D, Hayden A *et al.* Prognosis of chronic unexplained dyspepsia. A prospective study of potential predictor variables in patients with endoscopically diagnosed nonulcer dyspepsia. *Gastroenterology* 1987; **92**: 1060–1066.
10. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. *Am J Gastroenterol* 2001; **96**: 1340–1349.
11. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. *Lancet* 1994; **343**: 811–816.
12. Gisbert JP, Pajares JM. Helicobacter pylori "test-and-treat" strategy for dyspeptic patients. *Scand J Gastroenterol* 1999; **34**: 644–652.
13. Gisbert JP, Pajares JM. Helicobacter pylori "test-and-scope" strategy for dyspeptic patients. *Helicobacter* 2000; **5**: 57–68.
14. Gisbert JP, Cruzado AI, Benito LM *et al.* Helicobacter pylori "test-and-scope" strategy for dyspeptic patients. Is it useful and safe? *Dig Liver Dis* 2001; **33**: 539–545.
15. Tack J, Talley NJ, Camilleri M *et al.* Functional gastroduodenal disorders. *Gastroenterology* 2006; **130**: 1466–1479.
16. Gear MW, Wilkinson SP. Open-access upper alimentary endoscopy. *Br J Hosp Med* 1989; **41**: 438–40, 42–4.
17. Heaney A, Collins JS, Watson RG *et al.* A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. *Gut* 1999; **45**: 186–190.
18. Jones R, Tait C, Sladen G *et al.* A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. *Int J Clin Pract* 1999; **53**: 413–416.
19. Lassen AT, Pedersen FM, Bytzer P *et al.* Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. *Lancet* 2000; **356**: 455–460.
20. McCoil KE, Murray LS, Gillen D *et al.* Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. *BMJ* 2002; **324**: 999–1002.
21. Arents NL, Thijs JC, van Zwet AA *et al.* Approach to treatment of dyspepsia in primary care: a randomized trial comparing "test-and-treat" with prompt endoscopy. *Arch Intern Med* 2003; **163**: 1606–1612.
22. Hu WH, Lam SK, Lam CL *et al.* Comparison between empirical prokinetics, Helicobacter test-and-treat and empirical endoscopy in primary-care patients presenting with dyspepsia: a one-year study. *World J Gastroenterol* 2006; **12**: 5010–5016.
23. Mahadeva S, Chia YC, Vinothini A *et al.* Cost-effectiveness of and satisfaction with a Helicobacter pylori "test and treat" strategy compared with prompt endoscopy in young Asians with dyspepsia. *Gut* 2008; **57**: 1214–1220.
24. Duggan AE, Elliott CA, Miller P *et al.* Clinical trial: a randomized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care. *Aliment Pharmacol Ther* 2009; **29**: 55–68.
25. Gisbert JP, Pajares JM. [Rapid whole blood test for the diagnosis of H. pylori infection. Can it be recommended for the diagnosis of the infection in clinical practice?]. *Med Clin (Barc)* 2002; **118**: 196–197.
26. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. *Gut* 2004; **53**: 1758–1763.
27. Manes G, Menchise A, De Nucci C *et al.* Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. *BMJ* 2003; **326**: 1118.
28. Jarbol DE, Kragstrup J, Stovring H *et al.* Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. *Am J Gastroenterol* 2006; **101**: 1200–1208.
29. Delaney BC, Qume M, Moayyedi P *et al.* Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). *BMJ* 2008; **336**: 651–654.
30. Ford AC, Moayyedi P, Jarbol DE *et al.* Meta-analysis: Helicobacter pylori "test and treat" compared with empirical acid suppression for managing dyspepsia. *Aliment Pharmacol Ther* 2008; **28**: 534–544.
31. Jarbol DE, Bech M, Kragstrup J *et al.* Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori test for management of dyspepsia: a randomized trial in primary care. *Int J Technol Assess Health Care* 2006; **22**: 362–371.
32. Moayyedi P. Helicobacter pylori test and treat strategy for young dyspeptic patients: new data. *Gut* 2002(50 Suppl 4): iv47–iv50.
33. Ford AC, Moayyedi P. Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care? *Pol Arch Med Wewn* 2009; **119**: 391–396.
34. Ford AC, Qume M, Moayyedi P *et al.* Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. *Gastroenterology* 2005; **128**: 1838–1844.
35. Delaney B, Ford AC, Forman D *et al.* WITHDRAWN: initial management strategies for dyspepsia. *Cochrane Database Syst Rev* 2009 CD001961.
36. Moayyedi P, Zilles A, Clough M *et al.* The effectiveness of screening and treating Helicobacter pylori in the management of dyspepsia. *Eur J Gastroenterol Hepatol* 1999; **11**: 1245–1250.
37. Joosen EA, Reininga JH, Manders JM *et al.* Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice. *Eur J Gastroenterol Hepatol* 2000; **12**: 319–325.
38. Madisch A, Hotz J, Grabowski G *et al.* Efficacy of Helicobacter pylori eradication in uninvestigated chronic dyspeptic staff members of a large factory: a prospective, long-term, follow-up, workplace outcome study. *Eur J Gastroenterol Hepatol* 2002; **14**: 61–69.
39. Farkkila M, Sarna S, Valtonen V *et al.* Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. *Scand J Gastroenterol* 2004; **39**: 327–335.
40. Gisbert JP, Badia X, Roset M *et al.* The TETRA study: a prospective evaluation of Helicobacter pylori "test-and-treat" strategy on 736 patients in clinical practice. *Helicobacter* 2004; **9**: 28–38.
41. Pauker SG, Kassirer JP. Decision analysis. *N Engl J Med* 1987; **316**: 250–258.
42. Di Caro S, Cremonini F, Franceschi F *et al.* Helicobacter pylori test-and-treat strategy in the management of dyspepsia in primary care: an overview. *Scand J Gastroenterol* 2004; **39**: 297–302.
43. Barton PM, Moayyedi P, Talley NJ *et al.* A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States. *Med Decis Making* 2008; **28**: 44–55.
44. Chey WD, Fendrick AM. Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice. *Arch Intern Med* 2001; **161**: 2129–2132.
45. Chiba N, Van Zanten SJ, Sinclair P *et al.* Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. *BMJ* 2002; **324**: 1012–1016.
46. Fendrick AM, Chernew ME, Hirth RA *et al.* Alternative management strategies for patients with suspected peptic ulcer disease. *Ann Intern Med* 1995; **123**: 260–268.
47. Fendrick AM, Chernew ME, Hirth RA *et al.* Immediate endoscopy or initial Helicobacter pylori serological testing for suspected peptic ulcer disease: estimating cost-effectiveness using decision analysis. *Yale J Biol Med* 1996; **69**: 187–195.
48. Garcia-Altes A, Rota R, Barenys M *et al.* Cost-effectiveness of a 'score and scope' strategy for the management of dyspepsia. *Eur J Gastroenterol Hepatol* 2005; **17**: 709–719.
49. Gee I, Playford RJ, Turner D *et al.* Cost analysis of breath test versus endoscopy for dyspepsia. *Digestion* 2002; **65**: 207–212.
50. Klok RM, Arents NL, de Vries R *et al.* Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting. *Clin Ther* 2005; **27**: 1647–1657.
51. Ladabaum U, Chey WD, Scheiman JM *et al.* Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. *Aliment Pharmacol Ther* 2002; **16**: 1491–1501.
52. Makris N, Barkun A, Crott R *et al.* Cost-effectiveness of alternative approaches in the management of dyspepsia. *Int J Technol Assess Health Care* 2003; **19**: 446–464.
53. Marshall JK, Armstrong D, O'Brien BJ. Test and treat strategies for Helicobacter pylori in uninvestigated dyspepsia: a Canadian economic analysis. *Can J Gastroenterol* 2000; **14**: 379–388.
54. Mason J, Axon AT, Forman D *et al.* The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. *Aliment Pharmacol Ther* 2002; **16**: 559–568.
55. Moayyedi P, Soo S, Deeks J *et al.* Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. *Dyspepsia Review Group. BMJ* 2000; **321**: 659–664.
56. Ofman JJ, Etchason J, Fullerton S *et al.* Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. *Ann Intern Med* 1997; **126**: 280–291.
57. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. *Gastroenterology* 1996; **110**: 72–83.
58. Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. *Am J Gastroenterol* 1996; **91**: 1773–1777.

59. Sonnenberg A, Delco F, Inadomi JM. When to eradicate *Helicobacter pylori*? *Gastroenterol Int* 1997; **10**: 1–7.
60. Spiegel BM, Vakili NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. *Gastroenterology* 2002; **122**: 1270–1285.
61. Vakili N, Ashorn M. Cost-effectiveness of noninvasive testing and treatment strategies for *H. pylori* infection in children with dyspepsia. *Am J Gastroenterol* 1998; **93**: 562–568.
62. Bytzer P, Schaffalitzky de Muckadell OB. Prediction of major pathologic conditions in dyspeptic patients referred for endoscopy. A prospective validation study of a scoring system. *Scand J Gastroenterol* 1992; **27**: 987–992.
63. NIH Consensus Conference. *Helicobacter pylori* in peptic ulcer disease. NIH Consensus Development Panel on *Helicobacter pylori* in Peptic Ulcer Disease. *JAMA* 1994; **272**: 65–69.
64. Peura D. *Helicobacter pylori*: rational management options. *Am J Med* 1998; **105**: 424–430.
65. Dyspepsia – Management of Dyspepsia in Adults in Primary Care – Full Guidelines CG17 2004. London: NICE. Available from: <http://guidance.nice.org.uk/CG17/NICEguidance/pdf/English>. Accessed 18 July 2012.
66. Talley NJ, Vakili N. Guidelines for the management of dyspepsia. *Am J Gastroenterol* 2005; **100**: 2324–2337.
67. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol* 2007; **102**: 1808–1825.
68. Malfertheiner P, Megraud F, O’Morain CA *et al*. Management of *Helicobacter pylori* infection—the Maastricht IV/Florence Consensus Report. *Gut* 2012; **61**: 646–664.
69. Malfertheiner P, Megraud F, O’Morain C *et al*. Consensus report on management of *H. pylori* infection in press 2012.
70. Rotolo G, Dominguez LJ, Sarakatsianou V *et al*. Test-and-treat strategy for *Helicobacter pylori* (HP) infection in older patients. *Arch Gerontol Geriatr* 2010; **51**: 237–240.
71. Christie J, Shepherd NA, Codling BW *et al*. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. *Gut* 1997; **41**: 513–517.
72. Vakili N, Moayyedi P, Fennerty MB *et al*. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. *Gastroenterology* 2006; **131**: 390–401; quiz 659–660.
73. Talley NJ, Lam SK, Goh KL *et al*. Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia. *J Gastroenterol Hepatol* 1998; **13**: 335–353.
74. Management of Barrett’s esophagus. The Society for Surgery of the Alimentary Tract (SSAT), American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE) Consensus Panel. *J Gastrointest Surg* 2000; **4**: 115–116.
75. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. *Am J Gastroenterol* 2002; **97**: 1888–1895.
76. Axon AT, Bell GD, Jones RH *et al*. Guidelines on appropriate indications for upper gastrointestinal endoscopy. Working Party of the Joint Committee of the Royal College of Physicians of London, Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons, the British Society of Gastroenterology, and the Thoracic Society of Great Britain. *BMJ* 1995; **310**: 853–856.
77. de Wit NJ, Mendive J, Seifert B *et al*. Guidelines on the management of *H. pylori* in primary care: development of an implementation strategy. *Fam Pract* 2000; **17**(Suppl 2): S27–S32.
78. Delaney BC, Wilson S, Roalfe A *et al*. Randomised controlled trial of *Helicobacter pylori* testing and endoscopy for dyspepsia in primary care. *BMJ* 2001; **322**: 898–901.
79. Ladabaum U, Fendrick AM, Glidden D *et al*. *Helicobacter pylori* test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. *Am J Gastroenterol* 2002; **97**: 3007–3014.
80. Veldhuyzen van Zanten SJ, Bradette M, Chiba N *et al*. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. *Can J Gastroenterol* 2005; **19**: 285–303.
81. Hunt R, Thomson AB. Canadian *Helicobacter pylori* consensus conference. Canadian Association of Gastroenterology. *Can J Gastroenterol* 1998; **12**: 31–41.
82. Veldhuyzen van Zanten SJ. Can the age limit for endoscopy be increased in dyspepsia patients who do not have alarm symptoms? *Am J Gastroenterol* 1999; **94**: 9–11.
83. Delaney BC, Wilson S, Roalfe A *et al*. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. *Lancet* 2000; **356**: 1965–1969.
84. Talley NJ. Review article: dyspepsia: how to manage and how to treat? *Aliment Pharmacol Ther* 2002; **16**(Suppl 4): 95–104.
85. Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? *Am J Gastroenterol* 1999; **94**: 75–79.
86. Breslin NP, Thomson AB, Bailey RJ *et al*. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. *Gut* 2000; **46**: 93–97.
87. Dyspepsia: managing dyspepsia in adults in primary care. Available at [www.nice.org.uk/CG017NICEguideline](http://www.nice.org.uk/CG017NICEguideline).
88. Wallace MB, Durkalski VL, Vaughan J *et al*. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. *Gut* 2001; **49**: 29–34.
89. Canga C 3rd, Vakili N. Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. *Am J Gastroenterol* 2002; **97**: 600–603.
90. Bytzer P. Can noninvasive *Helicobacter pylori* testing save endoscopy? *Endoscopy* 1997; **29**: 649–651.
91. Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. *Am J Gastroenterol* 1999; **94**: 3122–3125.
92. Talley NJ, Vakili NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. *Gastroenterology* 2005; **129**: 1756–1780.
93. de Boer WA. Topics in *Helicobacter pylori* infection: focus on a ‘search-and-treat’ strategy for ulcer disease. *Scand J Gastroenterol Suppl* 2000; **232**: 4–9.
94. Go MF. Review article: natural history and epidemiology of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2002; **16**(Suppl 1): 3–15.
95. Bytzer P. Management of the dyspeptic patient: anything goes? *Am J Gastroenterol* 2006; **101**: 1209–1210.
96. Laheij RJ, Straatman H, Jansen JB *et al*. Evaluation of commercially available *Helicobacter pylori* serology kits: a review. *J Clin Microbiol* 1998; **36**: 2803–2809.
97. Feldman RA, Deeks JJ, Evans SJ. Multi-laboratory comparison of eight commercially available *Helicobacter pylori* serology kits. *Helicobacter pylori* Serology Study Group. *Eur J Clin Microbiol Infect Dis* 1995; **14**: 428–433.
98. Gisbert JP, de la Morena F, Abairra V. Accuracy of monoclonal stool antigen test for the diagnosis of *H. pylori* infection: a systematic review and meta-analysis. *Am J Gastroenterol* 2006; **101**: 1921–1930.
99. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of *Helicobacter pylori* infection – a critical review. *Aliment Pharmacol Ther* 2004; **20**: 1001–1017.
100. Vaira D, Vakili N. Blood, urine, stool, breath, money, and *Helicobacter pylori*. *Gut* 2001; **48**: 287–289.
101. Loy CT, Irwig LM, Katelaris PH *et al*. Do commercial serological kits for *Helicobacter pylori* infection differ in accuracy? A meta-analysis. *Am J Gastroenterol* 1996; **91**: 1138–1144.
102. McNulty C, Teare L, Owen R *et al*. Test and treat for dyspepsia—but which test? *BMJ* 2005; **330**: 105–106.
103. Duggan AE, Elliott C, Logan RF. Testing for *Helicobacter pylori* infection: validation and diagnostic yield of a near patient test in primary care. *BMJ* 1999; **319**: 1236–1239.
104. Agreus L, Talley N. Challenges in managing dyspepsia in general practice. *BMJ* 1997; **315**: 1284–1288.
105. Nocon M, Kuhlmann A, Leodolter A *et al*. Efficacy and cost-effectiveness of the 13C-urea breath test as the primary diagnostic investigation for the detection of *Helicobacter pylori* infection compared to invasive and non-invasive diagnostic tests. *GMS Health Technol Assess* advance online publication, 21 October 2009; 5: Doc14; doi:10.3205/hta000076.
106. McNulty C, Freeman E, Delaney B. *Helicobacter pylori* test & treat strategy for dyspepsia: a qualitative study exploring the barriers and how to overcome them. *Fam Pract* 2006; **23**: 203–209.
107. Calvet X, Lario S, Ramirez-Lazaro MJ *et al*. Accuracy of monoclonal stool tests for determining cure of *Helicobacter pylori* infection after treatment. *Helicobacter* 2010; **15**: 201–205.
108. Schwarzer A, Lottspeich C, Russmann H *et al*. Evaluation of a novel rapid one-step monoclonal chromatographic immunoassay for detection of *Helicobacter pylori* in stool from children. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 475–480.
109. Gisbert JP, Pajares JM. Diagnosis of *Helicobacter pylori* infection by stool antigen determination: a systematic review. *Am J Gastroenterol* 2001; **96**: 2829–2838.
110. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of *Helicobacter pylori* infection: a systematic review. *Helicobacter* 2004; **9**: 347–368.
111. Gisbert JP, Boixeda D, Martin de Argila C *et al*. [Why, when and how to treat *Helicobacter pylori* infection in gastroduodenal ulcer disease?]. *Rev Clin Esp* 1996; **196**: 610–621.
112. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. *Lancet* 2009; **374**: 1449–1461.
113. Chey WD, Moayyedi P. Review article: uninvestigated dyspepsia and non-ulcer dyspepsia—the use of endoscopy and the roles of *Helicobacter pylori* eradication and antisecretory therapy. *Aliment Pharmacol Ther* 2004; **19**(Suppl 1): 1–8.
114. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. *J Fam Pract* 1997; **44**: 545–555.
115. Tham TC, McLaughlin N, Hughes DF *et al*. Possible role of *Helicobacter pylori* serology in reducing endoscopy workload. *Postgrad Med J* 1994; **70**: 809–812.
116. Sobala GM, Crabtree JE, Pentth JA *et al*. Screening dyspepsia by serology to *Helicobacter pylori*. *Lancet* 1991; **338**: 94–96.
117. Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. *Am J Public Health* 1996; **86**: 200–205.
118. McColl KE, el-Nujumi A, Murray L *et al*. The *Helicobacter pylori* breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. *Gut* 1997; **40**: 302–306.
119. O’Riordan TG, Tobin A, O’Morain C. *Helicobacter pylori* infection in elderly dyspeptic patients. *Age Ageing* 1991; **20**: 189–192.
120. Patel P, Mendall MA, Khulusi S *et al*. Salivary antibodies to *Helicobacter pylori*: screening dyspeptic patients before endoscopy. *Lancet* 1994; **344**: 511–512.
121. Strauss RM, Wang TC, Kelsey PB *et al*. Association of *Helicobacter pylori* infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. *Am J Med* 1990; **89**: 464–469.
122. Dooley CP, Cohen H, Fitzgibbons PL *et al*. Prevalence of *Helicobacter pylori* infection and histologic gastritis in asymptomatic persons. *N Engl J Med* 1989; **321**: 1562–1566.

123. Barenys M, Rota R, Moreno V *et al.* [Prospective validation of a clinical scoring system for the diagnosis of organic dyspepsia]. *Med Clin (Barc)* 2003; **121**: 766–771.
124. Sipponen P, Varis K, Fraki O *et al.* Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. *Scand J Gastroenterol* 1990; **25**: 966–973.
125. Nomura A, Stemmermann GN, Chyou PH *et al.* Helicobacter pylori infection and the risk for duodenal and gastric ulceration. *Ann Intern Med* 1994; **120**: 977–981.
126. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. *Aliment Pharmacol Ther* 1995; **9**(Suppl 2): 59–69.
127. Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. *Aliment Pharmacol Ther* 2009; **30**: 791–815.
128. Forman D, Newell DG, Fullerton F *et al.* Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. *BMJ* 1991; **302**: 302–305.
129. Parsonnet J, Friedman GD, Vandersteen DP *et al.* Helicobacter pylori infection and the risk of gastric carcinoma. *N Engl J Med* 1991; **325**: 1127–1131.
130. Nomura A, Stemmermann GN, Chyou PH *et al.* Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991; **325**: 1132–1136.
131. Correa P. Is gastric carcinoma an infectious disease? *N Engl J Med* 1991; **325**: 1170–1171.
132. Gisbert JP, Boixeda D, Martín de Argila C. [Is gastric cancer an infectious disease?]. *Rev Esp Enferm Dig* 1996; **88**: 555–562.
133. Selgrad M, Bornschein J, Rokkas T *et al.* Clinical aspects of gastric cancer and Helicobacter pylori—screening, prevention, and treatment. *Helicobacter* 2010; **15**(Suppl 1): 40–45.
134. Rathbone M, Rathbone B. Helicobacter pylori and gastric cancer. *Recent Results Cancer Res* 2011; **185**: 83–97.
135. The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. *Lancet* 1993; **341**: 1359–1362.
136. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. *IARC Monogr Eval Carcinog Risks Hum* 1994; **61**: 1–241.
137. Basso D, Zambon CF, Letley DP *et al.* Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. *Gastroenterology* 2008; **135**: 91–99.
138. Ferreira RM, Machado JC, Leite M *et al.* The number of Helicobacter pylori CagA EPIYA C tyrosine phosphorylation motifs influences the pattern of gastritis and the development of gastric carcinoma. *Histopathology* 2012; **60**: 992–998.
139. Graham DY, Malaty HM, Go MF. Are there susceptible hosts to Helicobacter pylori infection? *Scand J Gastroenterol Suppl* 1994; **205**: 6–10.
140. Crabtree JE, Wyatt JL, Sobala GM *et al.* Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. *Gut* 1993; **34**: 1339–1343.
141. Hirai M, Azuma T, Ito S *et al.* High prevalence of neutralizing activity to Helicobacter pylori cytotoxin in serum of gastric-carcinoma patients. *Int J Cancer* 1994; **56**: 56–60.
142. Blaser MJ, Kobayashi K, Cover TL *et al.* Helicobacter pylori infection in Japanese patients with adenocarcinoma of the stomach. *Int J Cancer* 1993; **55**: 799–802.
143. Blaser MJ, Perez-Perez GI, Kleanthous H *et al.* Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. *Cancer Res* 1995; **55**: 2111–2115.
144. Malfertheiner P, Megraud F, O'Morain CA *et al.* Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. *Gut* 2012; **61**: 646–664.
145. Gisbert JP, Calvet X. Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. *Aliment Pharmacol Ther* 2011; **34**: 1047–1062.
146. Ruskone-Fourmestreaux A, Fischbach W, Aleman BM *et al.* EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. *Gut* 2011; **60**: 747–758.
147. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? *Hum Pathol* 1993; **24**: 569–570.
148. Gisbert JP. [Is gastric lymphoma an infectious disease?]. *Med Clin (Barc)* 1998; **110**: 56–61.
149. Parsonnet J, Friedman GD, Orentreich N *et al.* Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. *Gut* 1997; **40**: 297–301.
150. Mc Loughlin RM, Sebastian SS, O'Connor HJ *et al.* Review article: test and treat or test and scope for Helicobacter pylori infection. Any change in gastric cancer prevention? *Aliment Pharmacol Ther* 2003; **17**(Suppl 2): 82–88.
151. Fuccio L, Zagari RM, Eusebi LH *et al.* Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? *Ann Intern Med* 2009; **151**: 121–128.
152. Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology* 2006; **130**: 1377–1390.
153. Armstrong D. Helicobacter pylori infection and dyspepsia. *Scand J Gastroenterol Suppl* 1996; **215**: 38–47.
154. Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. *Gastroenterology* 1994; **106**: 1174–1183.
155. Gisbert JP, Boixeda D, Martín de Argila C *et al.* [Helicobacter pylori and non-ulcer dyspepsia: a pending matter]. *Rev Esp Enferm Dig* 1998; **90**: 441–453.
156. Moayyedi P, Deeks J, Talley NJ *et al.* An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. *Am J Gastroenterol* 2003; **98**: 2621–2626.
157. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. *Ann Intern Med* 2001; **134**: 361–369.
158. Laheij RJ, Jansen JB, van de Lisdonk EH *et al.* Review article: symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 1996; **10**: 843–850.
159. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. *BMJ* 1999; **319**: 1040–1044.
160. Danesh J, Lawrence M, Murphy M *et al.* Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. *Arch Intern Med* 2000; **160**: 1192–1198.
161. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on "Helicobacter pylori eradication in functional dyspepsia". *Arch Intern Med* 2011; **171**: 1936–1937.
162. Moayyedi P, Delaney BC, Vakil N *et al.* The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. *Gastroenterology* 2004; **127**: 1329–1337.
163. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. *Helicobacter* 2007; **12**: 275–278.
164. Malfertheiner P, Bazzoli F, Delchier JC *et al.* Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011; **377**: 905–913.
165. Gisbert JP, Calvet X, O'Connor A *et al.* Sequential therapy for Helicobacter pylori eradication: a critical review. *J Clin Gastroenterol* 2010; **44**: 313–325.
166. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. *Aliment Pharmacol Ther* 2011; **34**: 604–617.
167. Cochrissen A, Schiller R. Risks of H. pylori "test-and-treat" strategy in dyspepsia. *Am Fam Physician* 2008; **77**: 146.
168. Megraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. *Gut* 1998; **43**(Suppl 1): S61–S65.
169. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. *Gut* 2004; **53**: 1374–1384.
170. Megraud F, Coenen S, Versporten A *et al.* Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* 2012; **62**: 34–42.
171. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. *JAMA* 1997; **278**: 901–904.
172. Morrissey JF. The diagnosis of early gastric cancer. A survey of experience in the United States. *Gastrointest Endosc* 1976; **23**: 13–15.
173. Kahn KL, Greenfield S. The efficacy of endoscopy in the evaluation of dyspepsia. A review of the literature and development of a sound strategy. *J Clin Gastroenterol* 1986; **8**(3 Pt 2): 346–358.
174. Nyrén O, Adami HO, Gustavsson S *et al.* Social and economic effects of non-ulcer dyspepsia. *Scand J Gastroenterol Suppl* 1985; **109**: 41–47.
175. Williams B, Luckas M, Ellingham JH *et al.* Do young patients with dyspepsia need investigation? *Lancet* 1988; **2**: 1349–1351.
176. Olearczyk AS. Gastric carcinoma. A critical review of 243 cases. *Am J Gastroenterol* 1978; **70**: 25–45.
177. Maconi G, Kurihara H, Panizzo V *et al.* Gastric cancer in young patients with no alarm symptoms: focus on delay in diagnosis, stage of neoplasm and survival. *Scand J Gastroenterol* 2003; **38**: 1249–1255.
178. Thomson AB, Barkun AN, Armstrong D *et al.* The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment—Prompt Endoscopy (CADET-PE) study. *Aliment Pharmacol Ther* 2003; **17**: 1481–1491.
179. Hammer J, Eslick GD, Howell SC *et al.* Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. *Gut* 2004; **53**: 666–672.
180. Bustamante M, Ferrando MJ, Devesa F *et al.* [The prediction of the endoscopic diagnosis in the dyspepsia patient: the value of the predominating presenting symptom and the initial clinical presumption]. *Gastroenterol Hepatol* 2000; **23**: 66–70.
181. Li XB, Liu WZ, Ge ZZ *et al.* Helicobacter pylori "test-and-treat" strategy is not suitable for the management of patients with uninvestigated dyspepsia in Shanghai. *Scand J Gastroenterol* 2005; **40**: 1028–1031.
182. Nakajima S. Stepwise diagnosis and treatment from uninvestigated dyspepsia to functional dyspepsia in clinical practice in Japan: proposal of a 4-step algorithm. *Digestion* 2009; **79**(Suppl 1): 19–25.
183. Li XB, Liu WZ, Ge ZZ *et al.* [Safety of Helicobacter pylori 'test-and-treat' strategies for the management of uninvestigated dyspepsia]. *Zhonghua Nei Ke Za Zhi* 2005; **44**: 195–197.
184. Howell S, Talley NJ. Does fear of serious disease predict consulting behaviour amongst patients with dyspepsia in general practice? *Eur J Gastroenterol Hepatol* 1999; **11**: 881–886.
185. Hu WH, Wong WM, Lam CL *et al.* Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. *Aliment Pharmacol Ther* 2002; **16**: 2081–2088.
186. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. *Br J Gen Pract* 1999; **49**: 451–453.
187. Laheij RJ, van Rossum LG, Heinen N *et al.* Long-term follow-up of empirical treatment or prompt endoscopy for patients with persistent dyspeptic symptoms? *Eur J Gastroenterol Hepatol* 2004; **16**: 785–789.



188. Slade PE, Davidson AR, Steel A *et al.* Reducing the endoscopic workload: does serological testing for *Helicobacter pylori* help? *Eur J Gastroenterol Hepatol* 1999; **11**: 857–862.
189. Bowie PE, Cox RA, Davidson AR *et al.* Young dyspeptic patients: with a test-and-treat policy, are the benefits of decreased symptom severity and oesophago-gastric-duodenoscopy workload sustained? *Eur J Gastroenterol Hepatol* 2001; **13**: 541–545.
190. Zar S, Mendall MA. Clinical practice—strategies for management of dyspepsia. *Br Med Bull* 1998; **54**: 217–228.
191. Stanghellini V, Tosetti C, Barbara G *et al.* Management of dyspeptic patients by general practitioners and specialists. *Gut* 1998; **43**(Suppl 1): S21–S23.
192. Seifert B, Rubin G, de Wit N *et al.* The management of common gastrointestinal disorders in general practice A survey by the European Society for Primary Care Gastroenterology (ESPCG) in six European countries. *Dig Liver Dis* 2008; **40**: 659–666.
193. Vaira D, Stanghellini V, Menegatti M *et al.* Prospective screening of dyspeptic patients by *Helicobacter pylori* serology: a safe policy? The Italian *Helicobacter pylori* Study Group. *Endoscopy* 1997; **29**: 595–601.
194. Mahadeva S, Connelly J, Sahay P. A test-and-treat policy does not save endoscopy workload in a non-referral hospital. *Eur J Gastroenterol Hepatol* 2002; **14**: 257–262.
195. Weingarten S. Translating practice guidelines into patient care: guidelines at the bedside. *Chest* 2000; **118**(2 Suppl): 4S–7S.
196. Bero LA, Grilli R, Grimshaw JM *et al.* Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. *BMJ* 1998; **317**: 465–468.
197. Weijnen CF, de Wit NJ, Numans ME *et al.* Dyspepsia management in primary care in The Netherlands: to what extent is *Helicobacter pylori* diagnosis and treatment incorporated? Results from a survey among general practitioners in The Netherlands. *Digestion* 2001; **64**: 40–45.
198. Graham DY. The only good *Helicobacter pylori* is a dead *Helicobacter pylori*. *Lancet* 1997; **350**: 70–71; author reply 2.
199. McColl K. Should non-invasive *Helicobacter pylori* testing replace endoscopy in investigation of dyspepsia? *Helicobacter* 2000; **5**(Suppl 1): S11–S15.



**Clinical and Translational Gastroenterology is an open-access journal published by Nature Publishing Group.**  
**This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>**